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According to the Joint United Nations Programme on HIV/AIDS (UNAIDS) South Africa 2010 Country 
Progress report, 81% of South African children in need of antiretroviral therapy (ART) were receiving 
treatment which is a 20% increment in treatment access from 2008 to 2009. With increase in access 
to treatment, understanding drug tolerability, safety and durability is important especially among 
children whose drug options are limited due to few drugs being available in suitable formulations 
and the need for refrigeration of some drugs. While there are many paediatric studies on ART 
durability in the developed world, data from the developing world are limited. There is therefore a 
need to understand the drug-specific probability of and reasons for drug stops or changes among 
children initiated on ART in South Africa. This knowledge could help in optimisation of use of first-
line ART in order to maximise time on first-line therapy and thereby maintain simplicity of programs 
(program-level benefit) and save alternative drugs for situations of toxicity and virological failure 
(individual benefit). We determined the probability of and reasons for stopping/changing of 
antiretroviral drugs in the International epidemiological Databases to Evaluate AIDS Southern Africa 
(IeDEA-SA) paediatric data. 
Methods: 
This study was a secondary analysis of cohort data which are routinely collected from all paediatric 
HIV clinic sites in South Africa that contribute data to the IeDEA-SA Collaboration. The study 
population included all HIV infected children ≤16 years of age at ART initiation with a documented 
date of birth and initial regimen of ≥3 antiretroviral (ARV) drugs, and attending any one of 7 South 
African paediatric HIV clinic sites that contribute data to the IeDEA-SA database. The time from 
initiation of ART to first treatment change both for the entire regimen (mainly due to treatment 
failure) and for individual drugs was described using the Kaplan-Meier method. Competing risks 
analysis was used to determine the reasons for drug-specific changes. Predictors of specific drug 














Data from 5517 children with median [IQR] age at ART start of 42 [15-82] months were included in 
the analysis. By 3 years on ART, 81% of children alive and in care were still taking their initial 
regimen. Drug stops/changes for reasons other than treatment failure were mainly due to potential 
drug interaction in the 1st year on therapy (2.9%) while in the 3rd year toxicity (3.1%), potential drug 
interaction (2.6%), treatment simplification (e.g. changing from syrup to tablet formulations) (2.3%)  
and other unspecified reasons (4.1%) were the main contributors. Nevirapine, zidovudine and 
stavudine were responsible for most treatment-limiting toxicity by 2 years on ART i.e. n=10/259 
(4%), n=11/602 (2.8%) and n=45/4883 (1.4%) respectively. Nevirapine toxicity occurred almost 
entirely in the first six months whereas stavudine toxicity occurred mostly after 1 year of therapy. 
Half of the zidovudine toxicity occurred in the first 3 months with the remainder evenly spread over 
the following 21 months. 
 
Conclusion 
Paediatric ART durability in resource-limited settings is good but complex, with treatment changes 
not only due to toxicity, treatment failure and drug interactions, but also treatment simplification. 
NVP, AZT and d4T are responsible for most of the treatment-limiting toxicity in children in resource-
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PART A: PROTOCOL 
SUBSTITUTIONS TO INITIAL ANTIRETROVIRAL THERAPY DUE TO TOXICITY OR CONTRAINDICATION 
IN CHILDREN IN SOUTH AFRICA 
I. INTRODUCTION  
Southern Africa has a high burden of paediatric HIV, and despite recent massively expanded access 
to antiretroviral therapy (ART), coverage remains low. By the end of 2009, 81% of South African 
children in need of ART were receiving treatment which is a 20% increment in one year from 2008 
[1]. However, these data do not account for children lost to follow-up, transferred out of care or 
who had died or remained undiagnosed.  
With increased access to ART, many children in South Africa and other parts of the world may have 
one or more drugs in their initial antiretroviral (ARV) regimen changed during therapy. Regimen 
changes can be considered as either (i) one or more drug substitutions for reasons other than 
treatment failure while keeping the same overall regimen, e.g. a change from stavudine (d4T) to 
zidovudine (AZT) in a child with lipodystrophy, with all other drugs in the regimen remaining the 
same (which will be referred to as “substitutions”) or (ii) a complete switch of the regimen due to 
treatment failure in which there is a change from a non-nucleoside reverse transcriptase inhibitor 
(NNRTI) to a protease inhibitor (PI) or vice versa together with a change of at least one of the 
nucleoside reverse transcriptase inhibitors (NRTI) (which will be referred to as “switches”). Reasons 
for regimen or drug change reported by previous studies of paediatric ART outcomes include serious 
adverse events, treatment failure, co-treatment for tuberculosis (TB), policy/guideline changes and 
drug stock outs [2-7]. In these studies, the median time to treatment change regardless of whether 














II. PROBLEM IDENTIFICATION:  
Understanding regimen durability is particularly important in resource-limited settings with limited 
drug options [8]. This is especially so for children [9] due to limited palatable paediatric formulations, 
the need for refrigeration of liquid formulations which may not be feasible in resource-poor settings 
and lack of incentive for pharmaceutical companies to manufacture paediatric ARV drugs due to a 
small market especially in resource rich countries [10].  
While the frequency and determinants of regimen switch in children with virological failure in South 
Africa have been examined [11], there is very little data from South Africa or other developing 
countries on the frequency of drug substitutions for reasons other than treatment failure.  
III. LITERATURE REVIEW: 
We aim to review all paediatric observational studies from resource limited settings reporting on 
regimen changes in children on ART. Selected key articles from the adult literature on regimen 
changes in developing countries as well as studies from developed countries will also be reviewed 
for comparison with and to contextualise the paediatric studies. In addition, selective randomised 
controlled trials reporting on toxicity of ART will also be included as determining drug safety is one of 
the main reasons for studying regimen changes. 
ART regimen changes are fairly common in routine HIV care albeit less common in developing 
countries compared to developed countries [8, 9] probably due to fewer alternative regimens in the 
developing countries, hence the importance of determining the frequency and reasons for them.  
Alternatives to the first-line ART recommended in national guidelines are limited and should ideally 
be preserved for situations of virological failure or serious adverse events. This is a particular 
concern in children for whom ART options are limited due to the need for palatable formulations of 
ART in which small dosing increments are possible. In addition, prior exposure to prevention of 
mother to child transmission (PMTCT) regimens predisposes these children to resistance to the 












reducing the options available for use as first-line regimens and/or alternative regimens among 
children.  
3.1 ART drug substitution in adults 
In Africa and elsewhere in the world, most large cohort studies done to determine the tolerability 
and reasons for first-line ART change have been conducted in adults.  Boulle et al (2007), in a study 
conducted to determine the probability of substitutions due to ARV toxicity or contraindication in 
the first three years of therapy in 2 South African cohorts reported that 72% of 2679 adults 
remained on their initial NNRTI-based regimen after 3 years of treatment. Substitutions of d4T were 
the most common and accumulated over time, with patients having a 21% cumulative probability of 
having their treatment substituted by 3 years on ART. In contrast, cumulative probabilities of 
substitutions due to toxicity of NVP (8%), efavirenz (EFV) (2%) and AZT (8%) were less frequent and 
occurred early on after starting ART. Another prospective cohort of 559 adult patients in Uganda, 
most of whom were started on NVP-based (74%) or EFV-based first-line ART, reported that about a 
quarter of the cohort had at least one treatment change fter a median follow-up time of 33 (IQR, 
24 to 34) months on ART. Drug toxicity accounted for the majority of first treatment changes (62%) 
followed by treatment failure (16.2%) with the remainder of the regimen changes being due to 
TB/HIV co-infection and pregnancy [13]. d4T toxicity was found to be the main reason for drug 
substitution due to toxicity and was associated with being female and WHO stage 3 or 4 and this 
concurs with Boulle et al (2007). The median time to substitution was 2 (IQR, 0.45 to 1.09) years. In 
addition, other developing country adult studies assessing initial response to ART, its durability and 
tolerability have also found that toxicity contributed most to both inter and intra-class single drug 
substitutions [14-16]. 
3.2 ART drug substitution in children  
In comparison to adult studies, data on the durability and tolerability of ARVs in children are 
restricted as there are few large paediatric cohort studies that have been conducted and most data 












overlapping toxicities; there are also drug and class-specific toxicities [17, 18] hence the need to 
clearly document the drug limiting toxicities associated with ART in children as extrapolating results 
from adult studies to children may be inaccurate. A cohort study conducted to describe outcomes of 
ART-naïve severely immune suppressed children less than 5 years old and receiving ART in resource 
limited settings, 90% of whom were in Africa and the rest in Asia; showed that after a median time 
of 1.5 (IQR, 0.7-5.7) months on highly active antiretroviral therapy (HAART), 3.8% of these children 
had one or more of their first-line ARV drugs changed mainly due to toxicity. The first-line regimen 
was d4T/3TC/NVP for children aged between 12 to 59 months with AZT replacing d4T for those who 
were 12 months and younger. In African children, AZT toxicity was more frequent while in Asian 
children, toxicity was mainly due to NVP. Switching to second-line drugs was more common in 
African children (87.9% of all switches) after about 27 months on ART [19].  
In contrast, Davies et al (2011), in a study designed to determine the probability of virological failure 
and switching to second-line ART in children in South Africa found that ART-naïve South African 
children aged less than 16 years had a 19% probability of failing treatment by 36 months on therapy 
with a 38% switch rate in those with at least 1 year of follow-up after failure. The switches occurred 
a median of 5.7 (IQR, 2.9-11.0) months after treatment failure was diagnosed. This study, however, 
did not aim to examine reasons for ARV regimen substitution which may include toxicity, 
contraindication and change of eligibility criteria e.g. a child turning 3 years of age and changing 
from lopinavir/ritonavir (LPV/r) to EFV.  
A small number of studies report on reasons for ARV drug substitution including toxicity, treatment 
failure, initiation or completion of TB treatment and change due to increasing age [6, 20-23]. 
However, many of these cohorts are small with limited follow-up duration and the majority of 
children started on NNRTI-based treatment.  Tolerability of PI-based regimens in children has not 
been studied.  In addition, only the overall proportion of changes has been described with 















3.3 Studies from the developed world  
Most of the cohort studies done in the developed world have shown that the main reasons for ARV 
regimen changes in children are toxicity and treatment failure [24-28] and this is similar to findings 
from developing countries. For example, a retrospective cohort study of 110 HIV infected children in 
routine care in London, 83% of whom were not ART-naïve, found that the commonest cause of 
treatment change was virological failure (60%) and durability of first-line therapy was better (46 
weeks) compared to that of second (42 weeks) and third-line therapy (40 weeks) [29]. Tolerability of 
ART among children reduced as the treatment became more complex highlighting the importance of 
achieving maximum utility from standard first-line drugs before changing to an alternative drug to 
prevent situations where alternative regimens may run out. Other reasons for treatment change 
were toxicity and immunological failure in 10% and 6% of the children respectively [29] and this is 
consistent with findings from other cohort studies done in similar settings [24-28]. 
IV. JUSTIFICATION: 
With the scale up of ART in sub-Saharan Africa, knowledge of the tolerability and durability of first-
line ART is increasingly important as there are very few alternatives to standard first-line ARV 
regimens for children.  Due to the few available alternative drugs, if the durability of standard first-
line regimens is short, children may be placed on sub-optimal regimens increasing their risk of 
treatment failure and/or resistance.  Furthermore, substitution of single drugs in the first-line 
regimen for reasons other than failure, may limit the options for an effective second-line regimen 
when the child ultimately fails therapy. A number of observational studies on tolerability, safety and 
durability of first-line ART have been done in adult patients both in the developed and developing 
countries [8, 13-16]; however, there is still a paucity of information about the same in paediatric 
patients especially in low income settings such as South Africa. 
There are few available options for ART for use in HIV infected children, especially in Sub-Saharan 
Africa, due to lack of suitable formulations for children. There is thus a huge need to try to prevent 












therapy and save the few alternatives for situations of virological failure and/or drug resistance. This 
involves understanding the durability and tolerability of different ARV regimens and individual drugs.  
In addition, studying treatment-limiting toxicities will give us information about drug safety in clinical 
practice. In situations where drugs are changed or stopped for reasons of toxicity, studying such 
treatment-limiting toxicities will allow us to determine the rate of clinically important adverse 
events. Where standardized ART regimens are used, a change of a single drug due to toxicity 
indicates that the adverse event was severe enough for a clinician to stop the drug thought to have 
caused it. Accurate recording of all reasons for regimen changes ensures that under-ascertainment 
of event rates is minimized.  
V. RESEARCH QUESTION:  
What is the probability of and reasons for substitution of one or more drugs in an initial 
antiretroviral (ARV) regimen among South African children during the first three years on 
antiretroviral therapy (ART)? 
VI. RESEARCH AIM, OBJECTIVES AND HYPOTHESIS 
6.1 Aim: 
To determine the drug-specific probability of and reasons for drug change/stop among children 
initiated on ART in South Africa. 
6.2 Objectives: 
 To determine the cumulative probability of changing or stopping one or more drugs from an 
initial ARV regimen for each first-line drug among children on ART in South Africa. 
 To describe the reasons for changing or stopping one or more drugs from an initial ARV 
regimen for each first-line drug among children on ART in South Africa. 














a) There is an association between child characteristics and probability of and reasons for change of 
one or more ARV drugs in a regimen among children on ART. 
b) Drug substitutions will be rare in the IeDEA-SA cohort.  
VII. METHODS 
7.1 Study design: 
This will be a secondary analysis of cohort data routinely collected from children attending different 
paediatric HIV clinic sites in South Africa that contribute data to IeDEA-SA. These children are 
followed up routinely as part of standard HIV care and their response to ART is monitored. 
Treatment changes are made according to the South African National HIV Treatment Guidelines [30]. 
7.2 Population and sampling: 
7.2.1 Study Population:  
 This will include all HIV infected children who were below 16 years of age at the time of ART 
initiation and attend any of the South African paediatric HIV clinic sites that contribute data to the 
IeDEA database. These are Tygerberg Academic Hospital, Red Cross War Memorial Children’s 
Hospital, McCord Hospital, Rahima Moosa Mother and Child Hospital, Harriet Shezi Children’s HIV 
Clinic, Khayelitsha Community Health Centre and Gugulethu Community Health Centre.  The points 
of entry for the children into these cohorts include referral from other medical facilities and/or 
hospital wards, or being a family member of someone already attending the clinic. These patients 
attend these routine government clinics free of charge with the exception of McCord Hospital where 
patients contribute a small co-payment for screening and/or routine consultations. As 
recommended by the South Africa National Treatment Guidelines [30], these patients are followed 
up 1-2 monthly for the first 3-6 months on ART and 3 monthly thereafter especially if the patient is 













The standard first-line regimens across all the sites are d4T/3TC/ (LPV/r) for children 6 months to 3 
years of age or d4T/3TC/EFV if over 3 years of age and > 10kgs. The second-line regimen for children 
less than 3 years of age and commenced on a PI-based first-line regimen is AZT/ddI/NVP with EFV 
replacing NVP in children > 3 years of age. A second-line of AZT/ddI/ (LPV/r) is used for children 
commenced on an NNRTI-based first-line. Viral load and CD4 percentages are measured at least 6 
monthly across all sites.  
7.2.2 Sampling: 
This study will include all children less than 16 years old with complete data i.e. date of birth, 
gender, ART start date, initial ARV regimen, reasons and dates of regimen change or stop and from 
all paediatric HIV treatment sites in South Africa that contributed data to the IeDEA database up to 
March 2008.  
7.2.3 Inclusion criteria for cohorts: 
Only cohorts that initiated ART in at least 25 ART-naïve HIV-infected children will be included in the 
analysis. 
7.2.4 Inclusion criteria for children: 
 Children who commenced ART at <16 years of age  
 HIV-infected children who were ART-naïve at the time of ART initiation. 
 HIV-infected children who initiated ART with a documented initial regimen of at least 3 ARV 
drugs. 
7.2.5 Exclusion criteria for children: 
 All children with any missing information on key variables e.g. date of birth, gender and 
initial ARV regimen used will be excluded from the analysis. 
7.2.6 Sample size calculation: 
We will assume 90% power at a 0.05 level of significance for a two-sided test and a 0.2% overall 












which is slightly less than the 0.3% probability observed in resource rich settings [9]. Therefore, given 
a 20% anticipated censoring due to loss to follow-up from the study [31], entering the cohort 
immediately before database closure and transfer out of the cohort, the sample size will include at 
least 365 children [32]. 
7.3 Measurement: 
7.3.1 Instruments: 
Data are routinely collected from children during every clinic visit at the clinic sites. These data are 
kept in folders that are identified by unique patient numbers. Each site has a site-specific data 
collection form and data have been entered into a site-specific electronic database. Anonymised 
data are then transferred to the IeDEA database in various formats which i clude Access, XML, 
STATA and SAS where the data are converted to the SQL format and stored on the local server. 
While these data are void of any patient personal information (e.g. patient names), each patient has 
a unique and anonymous patient identifier that can easily be cross referenced by individual sites 
with the site database.  
Data from all seven cohorts that will be included in this analysis will be checked for completeness. 
Where data are found to be missing, for example, reasons for regimen substitution and the 
corresponding dates when the substitution was done; the sites will be contacted and requested to 
provide these data through folder review, and the combined IeDEA database updated accordingly. In 
addition, data on laboratory investigations done and opportunistic infections recorded during 
follow-up will be cross-checked to identify possible reasons for regimen change. 
7.3.2 Validity and Reliability: 
Validity and reliability of this study’s data collection tools is contingent upon that of the tools used at 
the HIV clinic sites for routine data collection. In order to check accuracy of these data, initial manual 
checking will be done to ensure that for every drug stopped, there is an appropriate stop reason and 
that drug start and stop dates are complete and coherent. Where inconsistencies are noticed or data 













The dependent variables will include: 
 Drug change –binary 
 Reasons for individual drug change- categorical e.g. toxicity, treatment simplification, 
potential drug interaction, treatment failure. 
The independent variables will include: 
 Age of the child at ART initiation-categorical i.e. <3years versus ≥3years 
 Gender- binary 
 CD4 percentage at ART initiation-continuous  
 WHO disease stage at ART initiation -categorical i.e. WHO stage 1 and 2 versus WHO stage 3 
and 4 
 Viral load at ART initiation -continuous 
 Initial ARV regimen used-nominal 
 Weight-for-age at baseline –categorical i.e. weight-for-age <-1 versus weight-for-age>=-1 
 Haemoglobin at ART initiation- categorical i.e. Haemoglobin <7g/dl versus haemoglobin 
≥7g/dl 
 Liver function tests values (e.g. alanine aminotransferase (ALT)) at ART initiation -continuous 
Data on potential confounders e.g. age, gender will be extracted from the IeDEA database and these 
will be adjusted for in the analysis using multivariate regression methods. 
In South African paediatric ART programs, laboratory monitoring (including CD4 testing, viral load 
testing, alanine transaminase (ALT) and haemoglobin testing) is available at all sites (either on-site or 
off-site) and the turnaround time for results varies between one day to 1 week. Patients are 
assessed clinically for adverse events at each clinical visit. Clinical visits are scheduled 1-2 monthly 
for the first 3-6 months on ART and approximately 3-monthly thereafter. In most programs, CD4 
monitoring, ALT and haemoglobin monitoring was done routinely every 6 months as recommended 
in national treatment guidelines during this period [30]. Lactate measurements were performed if 












VIII. DATA ANALYSIS 
8.1 Data management: 
All the patient folders are kept at the different paediatric HIV sites. During data transfer from the 
paediatric HIV sites, the data are encrypted and compressed using WinZip9 and the password is 
given to the IeDEA data manager either by fax or telephone (Appendix A). All patients have unique 
anonymised identifiers and no personal patient information e.g. names will be used for patient 
identification in the database. All electronic data are kept securely and managed by the IeDEA data 
manager and will be transferred into a STATA statistical package for the analysis. I will not have 
access to the main IeDEA database. 
Variables in the data set include but are not limited to: patient identifiers, cohort name, age, gender, 
first-line ART regimens, ART start and stop dates, alternative ART regimens given, visit dates, weight, 
height, laboratory tests done to monitor progress on treatment and any opportunistic infections 
(e.g. TB) suffered by children when on treatment. 
Using the data in STATA, I will manually check for missing data on dates of and reasons for regimen 
substitution, inconsistencies on regimens given, for example, patients on >4 ART drugs at any one 
time and duplicate drug records with identical start dates but different stop dates. A list of patients 
(using the IeDEA anonymous unique identifier) for whom there is missing or inconsistent data will be 
created for each site, and sites will be asked to provide the missing data and correct any 
inconsistencies by cross-checking with the site-level patient identifier and referring to original data 
collection forms and patient records. This will be followed by correction of data in the main IeDEA 
database which will only be done by the designated IeDEA data manager. 
8.2 Analysis plan: 
 For all analyses, techniques will be used that account for between cohort variation. Data will be 
analysed on an intention-to-treat basis in order to avoid an over estimation of treatment changes  
e.g. Children who had drug interruptions with the same drugs being re-started at a later date will be 












follow-up ended. Follow-up will be censored at the first of: first drug stop/change, date of death, 
date of transfer out, date of last visit if lost to follow-up or still in care at database closure. Analysis 
will be done using both univariate and multivariate methods. Characteristics of children at baseline 
and at time of treatment change will be described using univariate analysis i.e. medians and 
interquartile ranges if numerical but skewed, means and 95% Confidence Intervals (CIs) if numerical 
and normally distributed and proportions and 95% CIs for categorical variables. Multivariate analysis 
will be done to explore any associations between child-specific characteristics and specific drug 
treatment changes due to toxicity after adjusting for potential confounding variables.  
The Kaplan Meier method will be used to describe the time to first ART change for individual drug 
substitutions. For changes to the overall regimen, description of drug changes for each year will be 
done with the denominator being the number of children still in care at the end of that year. Survival 
curves will be plotted to show the different regimen change or single drug substitution events and 
risk tables will be included to show the number of children at risk of having a regimen or single drug 
substitution at different time intervals. Competing risks analysis will be used to determine the 
incidence of drug changes for specific reasons (e.g. d4T change due to lipodystrophy) in the sub-
population of children exposed to each specific drug.  The competing risks methods takes into 
account the fact that if a patient changed d4T for a competing reason (e.g. lactic acidosis) before the 
reason of interest (lipodystrophy), this drug could no longer be changed due to lipodystrophy. In 
other words, the competing risk is an event (changing d4T due to lactic acidosis), the occurrence of 
which precludes or alters the probability of the main event (d4T substitution due to lipodystrophy).  
Cox proportional hazards models will be used to identify independent predictors of individual drug 
changes due to toxicity for specific drugs in the initial ARV regimen (e.g. predictors of change of d4T 
due to toxicity). The Cox proportional hazards method will be used because it takes into account any 
losses to follow-up which a cohort study such as this one is vulnerable to and, stratification by site 
will be done to account for between site heterogeneity. These models will also be used to adjust for 
any confounders and/or effect modifiers in these paediatric cohorts. Confounders known to be 












ART initiation, CD4 count at ART initiation will be included in the model a priori. Interaction between 
some confounding variables and risk factors for ART drug substitution due to toxicity and between 
different risk factors will be investigated and any variables that are found to have interaction (i.e. 
which make a significant contribution to the model by significantly lowering the Aikaikes Information 
Criterion (AIC) and which are biologically plausible) will be included in the final model, while still 
maintaining parsimony. The final model will be chosen based on biological plausibility and will have 
the lowest AIC and largest log-likelihood. All analyses will be done using Stata 11.0 [32].  
IX. ETHICS AND COMMUNICATION: 
9.1 Ethics: 
The primary ethical issues that are likely to arise from this analysis will include beneficence, 
autonomy and justice. 
Beneficence implies that patients are not intentionally harmed and that benefits to patients are 
maximised and possible harms are minimised [33]. This analysis will pose no direct foreseen risk or 
harm to the patients since no further human subjects’ research will be done and only data routinely 
collected in the clinics will be used.  
Collection of these data was formally approved by the University of Cape Town Health Sciences 
Human Research Ethics Committee (Appendix B). 
Since this analysis will use data that do not contain personal patient identifiers e.g. names, 
confidentiality will be assured.  
A concept paper describing the type of analysis that will be done using these data will be circulated 
among the different IeDEA-SA sites and data will only be included in this analysis upon receiving 
permission from the participating sites to have their data used for this study (Appendix C).   
The concept of justice implies that patients’ rights should be considered when conducting any study. 
Despite the fact that this study will not directly benefit the children whose data will be used in this 
analysis, the results will be disseminated to the respective paediatric HIV clinics so as to inform and 












The results will also be widely disseminated to other health centres within and outside South Africa 
in order to improve management of HIV in children who need ART with regard to changing therapy.  
The results from this study will be aimed at informing policy regarding management of paediatric 
HIV and specifically concerning ART changes as this is a dilemma that is faced by health workers 
during the day to day routine care of children on ART. 
9.2 Stakeholders: 
 The stakeholders will include all the paediatric HIV clinic sites whose data will be used in this 
analysis, the children who attend these clinics, the policy makers in the field of HIV and the wider 
community. The researchers at the IeDEA both locally and internationally have a direct interest in 
this study since this analysis will use data from their database.  
9.3 Dissemination of study results: 
The results will be distributed electronically with the opportunity for an oral presentation at sites 
being offered. Abstracts will be submitted to relevant conferences (e.g. International AIDS Society 
(IAS) conference) to disseminate study results at the national and international level. Findings will be 
made available to other researchers in the field of infectious diseases by publishing results in the 
form of a manuscript in a peer-reviewed journal that will be identified. 
X. LOGISTICS 
10.1 Budget: 
As this will be a retrospective analysis of routinely collected data, the study will not incur any 
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XI. STUDY LIMITATIONS: 
 As this will be a retrospective analysis of routinely collected cohort data, the validity of this 
study’s results is contingent upon that of the data collected during a routine patient visit at 
the clinic sites. 
 Selection bias might affect our results if the children who are lost to follow-up or transferred 
out of the sites are different from those who are retained with regard to disease severity 
and ARV regimen changes or single drug substitutions. 
 This analysis will exclude all children with missing first-line regimens and if these children’s 
characteristics e.g. age, disease severity at treatment start are different from those whose 
data is available with regard to ARV regimen changes or single drug substitutions; this might 
introduce selection bias into the results. 
 The study is dependent on how well the data on regimen changes and/or drug substitution 
are collected and the variability in completeness of reasons for regimen substitution.  While 
reasons for all recorded drug changes will be sought, if the drug is completely unrecorded 
we will have no trigger to seek a reason for the change at the site where the child was being 
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PART B: STRUCTURED LITERATURE REVIEW 
Definition of regimen changes, substitutions and switches: 
For the purpose of this review, regimen changes were considered as either (i) one or more drug 
substitutions for reasons other than treatment failure while keeping the same overall regimen, e.g. a 
change from stavudine (d4T) to zidovudine (AZT) in a child with lipodystrophy, with all other drugs in 
the regimen remaining the same (which will be referred to as “substitutions”) or (ii) a complete 
switch of the regimen due to treatment failure in which there is a change from a non-nucleoside 
reverse transcriptase inhibitor (NNRTI) to a protease inhibitor (PI) or vice versa together with a 
change of at least one of the nucleoside reverse transcriptase inhibitors (NRTI) (which will be 
referred to as “switches”). Collectively all drug changes will be referred to as “changes” where there 
is no distinction being made between “substitution” and “switch”. 
I.   INTRODUCTION 
1.1 Aim:  
The aim was to review all published observational studies conducted on ART regimen changes (i.e. 
ART tolerability and durability) of ART in children both in developed and developing countries in 
order to evaluate the available evidence and identify gaps for further research. Selected key articles 
from adult literature on regimen changes from developed and developing countries were also 
reviewed for comparison with and to contextualise the paediatric studies. The review also draws 
upon paediatric studies on drug toxicity (including toxicity that did not lead to a drug change or stop) 
as toxicity is one of the main reasons for drug changes among children taking ART both in developed 
and developing countries. Included studies were appraised for validity regarding selection of the 
study sample, sample size and methods used to monitor patients on treatment. Any discrepancies in 
the literature regarding reasons for individual drug change among children on ART were highlighted.  
1.2 Search strategy 
1.2.1 Search engines: Articles were searched for from the following online search engines: Pub med, 












1.2.2 Search terms: Key search terms were: [“substitution" OR "change" OR "durability" OR 
"tolerability" OR "toxicity” OR "switch"] AND ["ART" OR "HAART" OR "antiretroviral therapy" OR 
"antiretroviral treatment" OR “highly active antiretroviral therapy”]. 
1.2.3 Search strategy: The literature search was done using the search terms above and the articles 
found in the bibliographies of the chosen articles were examined and included if found to be 
relevant. Only articles in English were reviewed due to lack of resources to have non-English articles 
translated. 
1.2.4 Inclusion criteria for studies: 
All studies written in English from peer-reviewed journals whose primary objective was to 
investigate ART drug substitutions, stops, changes and/or switches in children and adults from both 
developing and developed countries published prior to 2012 were included. Any ART outcome 
studies among children in developing and developed countries that reported on ARV drug 
changes/stops as one of the outcomes were also included. Only observational studies e.g. cohorts 
and relevant systematic reviews were included as these are similar to our study and are likely to 
have similar criteria for drug change/stop. In addition, the purpose of the review was to focus on 
drug changes in routine clinical practice rather than study settings in which toxicity monitoring and 
criteria for change/stop might be different. Nevertheless, selective randomised controlled trials 
reporting on toxicity of ART were also included as determining drug safety is one of the main reasons 
for studying regimen changes.  
1.2.5 Exclusion criteria for studies: 




















FLOW DIAGRAM OF STUDIES CHOSEN 











1.3 Quality and relevance criteria of included studies 
A summary of the included studies is shown in the appended tables (Appendix D). Some studies 
were repeats on the same cohort [1, 2]. Studies were appraised for biases like selection bias (e.g. 
due to systematic error in selection of study participants or due to differential loss to follow-up with 
respect to both the exposure and outcome) and information bias, specifically detection bias in 
determining whether or not a child’s regimen needed to be changed. Differential loss to follow-up 
might have led to under-reporting of drug substitutions especially those due to toxicity if the 
children who were lost to follow-up experienced more toxicities than those retained but could not 
return because they were very ill.  
Studies included were both from developed and developing countries as the outcomes might be 
different given the difference in available resources e.g. laboratory monitoring of toxicity and 
response to treatment, classes and formulations of ARVs used as first-line therapy and availability of 
alternative regimens. These factors could affect the time taken to and reasons for change/stop of 
5 studies rejected 
because they were not 
written in English  
3 studies rejected because 
they were not follow-up 
studies so were not similar 
to our study 
4 studies rejected because 
they made no reference to 
drug stops/changes 
despite being outcome 
studies 
17 studies chosen and reviewed 













drugs. Studies from developing countries are especially important as these have the largest burden 
of people living with HIV yet resources are limited with frequently poorer access to laboratory 
monitoring and ARV drugs; hence the need to optimise use of available first-line regimens. 
II. LITERATURE REVIEW: 
Since the launch of the comprehensive ART program in South Africa, the number of children 
receiving ART has increased from 4200 to 152,000 between 2004 and 2011 [3]. This scale up of ART 
has led to a marked reduction in morbidity and mortality of children due to HIV; however, it has also 
been associated with increased incidence of toxicities [4] and treatment failure [5] which have in 
turn led to substitution and switching of therapy respectively. The World Health Organisation 
(WHO), in a bid to simplify care of HIV infected patients, has developed guidelines for the 
management of both adult and paediatric patients on ART including when their treatment should be 
changed and/or switched [6]. However, the available evidence to inf rm paediatric guidelines is 
limited because of limited data on long term toxicity and durability of paediatric ARV regimens in 
routine clinical practice. A fairly large number of cohort studies have been conducted to determine 
tolerability of ART among adults both in the developed and developing world but this remains an 
under-studied area among children on ART especially in developing countries.  
2.1 Studies dedicated to assessing ART regimen substitution/changes:  
Only one of 17 paediatric studies from the developing world [7] and none from the developed world 
were primarily focused on measuring the probability of ART regimen change/stop. A few of the adult 
studies, from both the developing and developed world [8-12] were dedicated to assessing the 
tolerability and durability of ART. The rest of the reviewed studies were aimed at investigating 
outcomes of ART, however, they reported on regimen changes/stops as one of their outcomes, but 
not in detail. 
2.2 Sample size: 
The paediatric observational studies had variable sample sizes ranging from 32 to 6151 participants 
with two of the large cohorts being multi-regional [4, 13]. Both the adult and paediatric cohorts from 












numbers may mean that estimates of risk of drug changes are not precise, one may not detect a 
difference in risks of different drug changes where there is one, and rare causes of drug change may 
not be observed. While collaborative cohorts may have large numbers of participants, data quality 
may not be as good. For example, some cohorts might have missing data, definitions of changes and 
coding of reasons for changes may differ between cohorts and some changes or reasons for change 
may be missed leading to under-reporting of results. 
2.3 Study participant characteristics: 
The paediatric cohorts from developed countries have relatively younger children [14-18] compared 
to those from developing countries [1, 2, 4, 7, 13, 19-21] with the median age of children ranging 
from 2-7 years in the former and from 4-10 years in the latter. This could be a result of the fact that 
in developed countries children are likely to initiate ART soon after being diagnosed with HIV rather 
than waiting until they meet ART initiation criteria that restrict ART to those with particular clinical 
or immunological criteria as is the case in most resource-limited settings. In addition, access to HIV 
care may be better in developed than developing countries. In some developing countries like South 
Africa, immediate treatment of all HIV infected infants has only been recently included in the HIV 
treatment guidelines [22]. 
2.4 Sample selection: 
Most studies enrolled all the eligible children who were taking ART during the duration of the study. 
Some used data from paediatric HIV registers [18] and others from cohorts of HIV-infected children 
on ART who regularly attended HIV/AIDS clinics or ART programs in hospitals [13, 14, 19, 23]. These 
studies were not affected by selection bias since they enrolled all eligible children into their cohorts 
at ART initiation, however, validity and reliability of data from registers is reliant on good record 
keeping. In situations where the registers are incomplete, there might be over or under-estimation 
of ART durability. 
Most of these children were referred to these clinics from either public hospitals or centres of 
excellence with some research capacity [1, 2, 4, 16, 24-26] therefore the private sector is not well 












would be accessing HIV care in public health facilities or centres of excellence which would be 
affiliated with government hospitals. Being at a centre with research capacity means that there is 
better access to laboratory monitoring of toxicity  and to alternative drugs and formulations hence 
there might be more frequent changes compared to more poorly resourced settings. All of the study 
participants in the adult cohorts were enrolled from routine ART programs both in developing and 
developed countries. In some of the adult studies, all the patients attending these programs were 
enrolled into the cohort study [9-11, 27, 28] while for the rest, consecutive sampling was used to 
enrol patients into the study until the desired sample size was attained [8, 12].  
2.5 First-line ART regimens used: 
Patients in cohorts from developed countries initiated therapy using NNRTI and/or PI-based ART 
regimens [14-18] while those in developing countries initiated therapy using mainly NNRTI-based 
ART [13, 19, 20, 23, 29] with the exception of South African and some West African cohorts where 
children initiated therapy using PIs [1, 2, 24, 26, 30]. Therefore changes made to NNRTI-based 
regimens have been better studied than PI-based treatment in resource-limited settings. 
2.6 Monitoring of study patients: 
There was a difference between monitoring of children in developed and developing country 
settings. While most developed country paediatric cohorts monitored their patients using 6 monthly 
absolute CD4 count/percent, viral load measures and/or clinical improvement; those in developing 
countries mainly used CD4 count and/or clinical improvement [7, 13, 19, 21, 23]. There was a lot of 
variability in the reported median duration of treatment before drug change. Reasons for this might 
include different overall follow-up durations [2, 13, 23], different monitoring practices [2, 13, 23], 
different methods of reporting i.e. it is not explicitly stated if this median time to drug change only 
included children who had a regimen change or all children who initiated therapy in the 
denominator. Most children had clinical evaluations every 1-3 months [1, 7, 19, 21, 23], however, 
only the Kenyan children had extensive laboratory tests done e.g. complete blood counts and 
alanine aminotransferase (ALT) at baseline and every 3 months after ART initiation [19]. This may 












cohorts since they were not being actively monitored. With the exception of Hawkins et al (2007); all 
the adult cohorts monitored their patients using both viral load and CD4 counts [8, 9, 12, 27].  
2.7 ART drug substitution:  
ART drug changes occurred more frequently in resource-rich settings [14-18] compared to resource-
poor settings [1, 2, 4, 7, 13, 16, 19-21, 23-26, 29-31] with virological failure and toxicity being the 
main reasons for change in both settings. For example, in a prospective cohort study in South Africa 
among 80 children starting therapy, 2 had a treatment change by a total follow-up time of 29.3 child 
years after ART initiation (24), while in another cohort study in the Netherlands, 8 of 32 children 
changed therapy by a median (range) of 1 (0.04-1.5) years on ART [15]. Reasons for this difference 
might include the fact that resource-rich settings have more drugs available, more regular and 
comprehensive monitoring both for toxicity and failure, lower thresholds for switching therapy (e.g. 
lower viral load thresholds used to define treatment failure) and individualized care rather than 
public health approach to regimen choice. The common treatment-limiting toxicities included: NVP-
associated skin rashes, AZT-induced anemia and ABC hypersensitivity. Other reasons for drug change 
included: concomitant TB treatment, drug dosing issues, treatment simplification (e.g. when a drug 
was not palatable, a child needed to change from a syrup to tablets or vice versa or changing to a PI-
sparing regimen in order to save PIs for second-line therapy), poor adherence, structured treatment 
interruption, drug shortages and NVP resistance due to previous exposure to monotherapy (i.e. 
single dose NVP for PMTCT) or dual therapy in the private sector. ART for children is thus complex 
with several factors to consider e.g. appropriate formulations for young children, drug palatability, 
need for small doses and small dose increments for infants and the challenge of storage 
requirements such as refrigeration of syrups and exposure to PMTCT regimens that may cause 
resistance. This also means that pharmaceutical companies have to manufacture different paediatric 
drugs in various formulations to meet the demand of different settings. However, because some 
formulations have short shelf lives, there is little financial incentive for companies to make them as 
production may not be profitable and demand may be low and erratic. This means that there isn’t 












2.7.1 Time to first drug substitution: 
None of the paediatric cohorts report on the cumulative probability of drug substitution. They only 
report the drug changes that were made and the median or mean time to these changes. This 
justifies the need to investigate the tolerability and durability of the initial ART regimen given to HIV 
infected children in developing countries, in this case, South Africa.  
2.8 Toxicity of HAART among children in resource limited settings: 
Toxicity has been identified as one of the main causes of treatment changes among children on 
HAART in both resource rich and resource poor settings and understanding toxicity Is an important 
reason for studying drug changes. Common toxicities in children include AZT-induced anemia; d4T-
induced lipodystrophy, peripheral neuropathy, lactic acidosis; NVP-induced hepatotoxicity and 
hypersensitivity, LPV/r-induced electrolyte abnormalities, gastrointestinal toxicities; ABC 
hypersensitivity and EFV associated psychiatric disturbances [33-39].  
2.8.1 Lipodystrophy: 
Lipodystrophy has been identified as one of the main toxicities associated with NRTIs especially d4T 
and didanosine (ddI) and while this is usually dependent on dosing and duration of therapy, d4T has 
been found to cause this toxicity even in standard paediatric doses [34] and there is no evidence 
about its reversibility [40].  
A cross-sectional study done in Uganda among 364 children aged 2-8 years who had been on ART for 
≥6 months found that 34% had metabolic abnormalities with 27% having lipodystrophy [35]. These 
children had been on ART for a longer duration compared to those who did not have lipodystrophy 
(mean (SD) duration of 3.5 (±1.3) and 3.1 (±1.2) years respectively) and were slightly older. 
Children’s adherence might be adversely affected as the physical features of lipodystrophy might 
identify a child as being HIV-infected with consequent HIV-related stigma [34]. 
2.8.2 Anemia: 
Unlike d4T; AZT toxicity (especially anemia) has not been widely studied in children in resource-
limited settings. In a retrospective cohort of 78 children in Thailand who had no haematological 












slight decline in haemoglobin [33]. These children had experienced immune recovery by the time of 
drug change, suggesting that the anemia was AZT-induced and not disease-associated. In addition, in 
a Jamaican cohort of 121 children 64% of whom were on ART; there was increased severity of 
anemia among those who were on AZT-based therapy (93%) [54]. A Nigerian cohort found a non-
significant increase in incidence of anemia among children taking AZT-based regimens compared to 
d4T-based ones. This was more pronounced among children who received cotrimoxazole 
prophylaxis and AZT. However, the numbers of those who did not get the prophylaxis for both d4T 
and AZT were too small to detect a difference between the groups so it is difficult to discern if this 
toxicity was a result of a synergistic effect between AZT and cotrimoxazole or only associated with 
AZT [41]. Results from the Anti-Retroviral Research for Watoto (ARROW) randomised trial in Uganda 
and Zimbabwe which is comparing AZT vs. no AZT toxicities in children might contribute to the 
limited evidence base when they are published [36].  
2.8.3 Hepatotoxicity: 
NVP has been found to be the leading cause of hepatotoxicity among patients on ART. Chu et al 
(2010) showed that after a median of 32 (IQR: 28-63) days on therapy, 1.4% of patients who had 
been taking NVP for ≥1 month developed hepatotoxicity. Those who had complete ALT monitoring 
had significantly higher incidence of hepatotoxicity (incidence rate (IR): 7.6 (95% CI: 4.8–12.1) per 
100 person-years) compared to those who did not (IR: 3.6 (95% CI: 1.8–7.2) per 100 person-years). 
This suggests that in settings where regular liver function monitoring is not available, there might be 
under-reporting or late diagnosis of NVP-associated hepatotoxicity. However, other studies have 
shown that regular hepatic function monitoring does not improve detection of clinically significant 
ART-induced hepatotoxicity [42, 43]. Incidence of liver toxicities may be increased by co-treatment 
of opportunistic infections like TB where Isoniazid use may increase the risk of hepatotoxicity [43]. 
2.8.4 Hypersensitivity:  
Hypersensitivity is associated with ABC and NVP therapy.  
o NVP hypersensitivity: While NVP-induced hypersensitivity has been found to be less 












especially if there is no slow dose escalation at ART initiation e.g. in a phase I trial to 
determine NVP  safety among children, 1 in 21 children experienced a NVP-related rash [44]. 
This may complicate ART initiation in children as certain fixed dose combinations are not 
available in the doses needed for paediatric dose escalation, requiring the use of individual 
drugs at the start of therapy.  
o Abacavir hypersensitivity: Studies have shown that the incidence of ABC hypersensitivity is 
low ranging between 0.3-3.3% [46, 47] and mostly occurring within a month of initiating 
therapy among children aged less than 17 years. Misclassification of children on ABC as 
having hypersensitivity is common [47] emphasising the need for alerting caregivers to 
possible symptoms and frequent clinical monitoring especially during the first few months of 
ART initiation. Studies have shown that ABC hypersensitivity is associated with HLA-B57 [48], 
a marker that is more common among western populations than African ones explaining the 
higher incidence of ABC hypersensitivity in the former compared to the latter [49, 50]. 
2.8.5 Lactic acidosis:  
Lactic acidosis caused by d4T exposure in adults has been widely studied, but very little is known 
about it among children. Fielder and Rambiki (2010) describe a case of a family of 3 that developed 
lactic acidosis following therapy with d4T. The child developed it 2 years after initiating therapy (one 
year later than the parents); however, this was reversed when therapy was stopped. It is important 
that tests for blood lactate levels are available for patients who take d4T and clinicians should be 
aware of the relevant symptoms in order to change this drug as soon as the toxicity is detected.  
2.8.6 Peripheral neuropathy: 
Peripheral neuropathy is thought to be infrequent in young children but may also be under-reported 
as children may not self-report about reduced sensation in their extremities. So, despite it being one 
of the common d4T-induced toxicities there is very limited data about it in children. A prospective 
study in Kolkata, India found that only 1 of 100 children developed peripheral neuropathy after 2.5 
years of follow-up. Children were frequently clinically monitored (i.e. every 2, 4, 8, 12 and 24 weeks 












on treatment change due to peripheral neuropathy, while this is commonly reported as a reason for 
treatment change in adults [8, 9, 27]. 
2.8.7 Psychiatric disturbances: 
Psychiatric disturbances are commonly reported among patients taking EFV-based regimens. None 
of the reviewed paediatric or adult studies report on EFV-induced psychiatric disturbances. 
However, a review of neuropsychiatric effects of EFV in adults reveals contradictory evidence with 
some studies showing that ≥50% of patients experience temporary effects especially after the first 
dose, while others report long term effects [28, 52] with symptoms reducing with time [28]. While 
there are lots of studies about EFV-associated psychiatric effects in adults, paediatric data are 
lacking.  
2.8.8 Toxicity associated with PIs: 
Like d4T, PIs have also been found to be associated with abnormal fat redistribution. Other toxicities 
associated with PIs include:  gastrointestinal e.g. liver and pancreatic toxicities; nervous system, 
endocrine toxicities, cardiovascular, hypersensitivities, dyslipidaemias and haematological 
abnormalities e.g. thrombocytopenia [38].  
2.8.9 Dyslipidaemias:  
While dyslipidaemias may occur in ART naïve patients, they have been found to be common among 
children receiving ART. In a before and after sub study of the NEVEREST I trial of 195 South African 
children aged <2 years initiating ART with LPV/r-based regimens, there was a significant increase in 
all lipid profiles after 9 months on ART. This was, however, reversed for all but high density 
lipoproteins (HDL) in the NVP group after randomisation to either take NVP or maintain the PI [53].  
2.9 Summary and interpretation of literature: 
The reviewed literature shows that there are limited data on the tolerability and durability of ART in 
children. The outcome studies reviewed, which report on drug changes, reveal that initial ART drug 
changes are more frequent in developed countries compared to developing countries with the main 
reasons in both being virological failure and toxicity. This could be due to the fact that monitoring 












early on during treatment and the offending drugs changed. In addition, there are more alternative 
first-line drug options in developed countries compared to developing countries hence the higher 
frequency of ART changes in the former. Furthermore, the initial ART regimens used in developed 
countries are different than those used in developing countries and this could further explain the 
difference in the frequency of drug changes in the two settings. 
Unlike adult therapy, paediatric ART is complicated by the fact that there is reduced access to 
alternative drugs when toxicities occur especially in settings where most available drugs are given as 
fixed dose combinations. Paediatric programs have to work closely with their supply chain 
departments in order to ensure that there is adequate supply of alternative first-line drugs. This 
would also require that pharmaceutical companies increase production of different paediatric ART 
drugs in child-friendly formulations. 
2.10 Identification of needs for further research: 
There is a need for larger paediatric cohort studies dedicated to examining the tolerability and 
durability of first-line ART in developing and developed countries in order to identify drugs that are 
best tolerated by children so that these are considered for first-line therapy, adequately stocked and 
their use optimised. It is also important to identify the incidence of and risk factors for toxicity to 
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Background: Knowledge of the tolerability, safety and durability of first-line paediatric antiretroviral 
therapy (ART) regimens is vital to scaling up and maintaining children on therapy. We determined 
the probability of and reasons for stopping/changing of antiretroviral drugs in children from 7 South 
African sites in the International epidemiological Databases to Evaluate AIDS Southern Africa (IeDEA-
SA) collaboration. 
Methods: All ART-naïve children (< 16 years at ART initiation) with a documented initial regimen of 
≥3 antiretroviral drugs and ≥1 follow-up visit after initiation were included. The proportion of 
patients changing/stopping one or more drugs and the reasons for drug changes/stops were 
determined. The time from ART initiation to first treatment change/stop of ≥ 1 drug for toxicity was 
described using the Kaplan-Meier method. Competing risks analysis was used to determine the 
reasons for specific drug changes. Predictors of drug substitution due to toxicity were determined 
using Cox-proportional hazards models stratified by site. 
Results: 
Data from 5517 children with median [IQR] age at ART start of 42 [15-82] months were included in 
the analysis. By 3 years on ART, 81% of children alive and in care were still taking their initial 
regimen. Drug stops/changes for reasons other than treatment failure were mainly due to potential 
drug interaction in the 1st year on therapy (2.9%) while in the 3rd year toxicity (3.1%), potential drug 
interaction (2.6%), treatment simplification (e.g. changing from syrup to tablet formulations)  
(2.3%)and other reasons (4.1%)  were the main contributors. Nevirapine (NVP), zidovudine (AZT) and 
stavudine (D4T) were responsible for most treatment-limiting toxicity by 2 years on ART i.e. 
n=10/259 (4%), n=11/602 (2.8%) and n=45/4883 (1.4%) respectively. NVP toxicity occurred almost 
entirely in the first six months whereas d4T toxicity occurred mostly after 1 year of therapy. Half of 
















Paediatric ART durability in resource-limited settings is good but complex, with treatment changes 
not only due to toxicity, treatment failure and drug interactions, but also treatment simplification. 
NVP, AZT and d4T are responsible for most of the treatment-limiting toxicity in children in resource-
limited settings.  


































World Health Organisation (WHO) and developing country national Paediatric HIV treatment 
guidelines increasingly recommend universal antiretroviral therapy (ART) for infants and young 
children and/or commencement of ART at higher CD4 thresholds [1, 2]. This means that an 
increasing number of children in resource-limited settings are likely to initiate ART earlier in their 
disease course, with lower mortality and longer time spent on ART. It is thus important to 
understand the tolerability, durability and safety of paediatric ART. This can be used to optimise the 
use of drugs in first-line ART regimens and inform toxicity monitoring guidelines. While a number of 
adult studies describe the tolerability of ART regimens in both developed and developing countries 
[3-6], there are few paediatric studies that have specifically studied ART regimen changes in 
developing countries [7-9]. These studies report between 4.5%, and 19.4% of children changing ≥1 
drug in their non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART regimen, mainly due 
to toxicity and tuberculosis (TB) co-treatment. However, none of these studies report on the 
duration of therapy before treatment change. As these studies were conducted in small cohorts with 
limited follow-up duration, less common reasons for regimen change and those that only occur after 
longer ART durations may not have been described. A large number of cohort studies of paediatric 
ART outcomes report reasons for ART regimen modification. These include: starting/ending TB 
treatment while on ART, toxicities (e.g. stavudine (d4T)-induced lipodystrophy, zidovudine (AZT)-
induced anemia and nevirapine (NVP) hypersensitivity), treatment simplification (e.g. changing from 
syrups to tablets when a child is old enough to swallow them, changing drug or formulation when 
refrigeration requirements cannot be met), dosing issues, poor adherence and treatment failure. 
These studies were mostly done in children on NNRTI-based ART, so there are limited data on 
durability of protease inhibitor (PI)-based ART [8, 10-25].  
The International epidemiologic Database to Evaluate AIDS-Southern Africa (IeDEA-SA) collaboration 
includes relatively complete programmatic data on ART drug changes/stops from 7 South African 
paediatric ART programs with approximately 30% of children commencing PI-based first-line ART. 












antiretroviral drugs at South African IeDEA-SA paediatric sites, with a focus on drug changes due to 
toxicity. Risk factors for treatment –limiting toxicity were examined for each of the drugs most 
commonly stopped/substituted due to toxicity. 
Methods: 
Study design and population: 
Data was collected prospectively at each collaborating site and transferred anonymously to the 
IeDEA Data centers at the Universities of Bern and Cape Town.  The study was approved by the 
University of Cape Town Health Sciences Human Research Ethics Committee.  
All ART-naïve children <16 years of age at ART commencement with ≥1 follow-up visit after 
treatment initiation and initiated ART with a documented regimen of ≥3 antiretroviral drugs prior to 
March 2008 were included. As recommended by the South Africa National Treatment Guidelines 
[26], patients were followed up 1-2 monthly for the first 3-6 months on ART and 3 monthly 
thereafter.   
Treatment regimens used: 
At the time of data collection, the standard first-line regimens used were d4T/lamivudine 
(3TC)/lopinavir/ritonavir (LPV/r) for children 6 months to 3 years of age or d4T/3TC/ efavirenz (EFV) 
if over 3 years of age and >10kgs  [26]. Children <6 months of age were given RTV alone (due to lack 
of dosing recommendations for children <6 months of age) which was replaced with LPV/r when the 
child reached the age of 6 months while those who developed TB while on treatment had their 
treatment changed from LPV/r or NVP to RTV or RTV-boosted LPV/r if <3 years or weighed <10kgs 
while those who were ≥3 years and weighed >10kgs would be given EFV in place of NVP. 
Frequency of clinical and biological monitoring: 
While 2 of the clinics had paediatricians specifically providing HIV care, most of the clinics have 
physicians giving HIV care.  
Children are followed up clinically 1-2 monthly during the first 3-6 months after ART initiation, and, if 
stable, 2-3 monthly thereafter. While 2 of the clinics had paediatricians specifically providing HIV 












testing, viral load testing, alanine transaminase (ALT) and haemoglobin testing was available at all 
sites (either on-site or off-site) and the turnaround time for results varied from one day to 1 week in 
all clinics. In most clinics, CD4 measurement was done every 6 months except for Gugulethu where 
they were done 4 monthly. ALT and haemoglobin monitoring was done 6 monthly at all clinics 
except Khayelitsha where complete blood counts were done 12 monthly.  
Key Variables: 
Socio-demographic and clinical characteristics of children at baseline were described using means 
and 95% confidence intervals (CIs) for normally distributed numerical variables, medians and 
interquartile ranges for skewed numerical variables and proportions for categorical variables. Child 
characteristics included age, sex, first-line regimen and measures of disease severity (WHO Clinical 
Stage, CD4 percentage and absolute counts as well as the degree of immune suppression 
determined using the worst of CD4%/absolute according to WHO criteria) [27].        
Age and sex-standardized weight-for-age z-scores (WAZ) were calculated using the WHO 2006 
reference standards [28]. Age was included as a binary variable with a cut-off at 3 years because of 
different regimens being prescribed for children <3 yrs and ≥3 yrs. Severe anemia at ART start was 
defined as baseline haemoglobin (Hb) <7g/dl and age >21 days) as per the Division of AIDS grading of 
adverse events [28]. Lipodystrophy was defined as a disorder of fat metabolism characterised by loss 
of fat from or deposition of fat in tissue. 
Outcomes: 
The main outcomes included the time to the first drug change or stop for reasons other than non-
adherence and reasons for the change. Drug changes were considered as either (i) “Substitutions”: 
one or more drug substitutions/stops for reasons other than treatment failure while keeping the 
same overall regimen (e.g. a change from d4T to AZT in a child with lipodystrophy,  with all other 
drugs in the regimen remaining the same; or (ii) “Switches”: a complete switch of the regimen due 
to treatment failure in which there is a change from an NNRTI to a PI or vice versa together with a 














Data were analysed on an intention-to-treat basis in order to avoid an over estimation of treatment 
changes/stops e.g. children who had drug interruptions most likely due to missed appointments with 
the same drugs being re-started at a later date were therefore considered to still be at risk of having 
the drug changed until such a time as it was changed or when follow-up ended. Follow-up was 
censored at the first of: first drug stop/change, date of death, date of transfer out, date of last visit if 
lost to follow-up or still in care at database closure. The time from initiation of ART to first treatment 
change/stop was described using the Kaplan-Meier method. Only children with at least one follow-
up visit were included in the time-to-event analyses as a follow-up visit is needed for treatment to 
be change or stopped. Competing risks analysis was used to determine the incidence of drug 
changes for each specific reason (e.g. d4T change due to lipodystrophy) in the sub-population of 
children exposed to each specific drug. The competing risks method takes into account that if a 
patient changed d4T for a competing reason, the competing reason (e.g. lactic acidosis) led to the 
change of d4T before the reason of interest (lipodystrophy), this drug could no longer be changed 
due to lipodystrophy. In other words, the competing risk is an event (changing d4T due to lactic 
acidosis), the occurrence of which precludes or alters the probability of the main event (d4T 
substitution due to lipodystrophy). Cox-proportional hazards models stratified by site were used to 
determine the predictors of particular drug substitutions due to toxicity e.g. d4T substitutions due to 
toxicity. Potential confounders like age at ART initiation; viral load, CD4 count, and immune 
suppression at ART initiation were included in the multivariate model a priori.  WAZ was included as 
baseline fatness may confound lipoatrophy and lipohypertrophy assessment. The covariates were 
chosen based on previous literature showing their association with regimen-specific and/or drug-
specific changes in ART delivery.  For example, WAZ was included as a covariate as in adult studies a 
high body mass index at ART initiation is a risk factor for stavudine toxicity [4]. The best model was 
the one that was biologically plausible and had the lowest Aikaikes Information Criterion while 














The study population included all HIV infected children who were below 16 years of age at the time 
of ART initiation with a documented date of birth, gender and initial regimen of at least 3 ARV drugs.  
A total of 5517 children that initiated ART with a documented regimen prior to March 2008 at the 7 
South African paediatric ART programs were included in this analysis. Median age was 42 (15-82) 
months. Most were severely ill at ART initiation (i.e. 75% WHO stage 3/4 disease; 80% severely 
immune suppressed) (Table 1). First-line regimens including d4T were used by 89% of children, with 
the most common regimens being d4T/3TC/EFV (49%) followed by d4T/3TC/LPV/r (24%).  NVP/EFV 
was the “third drug” in the regimen for 60% of children.  Most of the children were still in follow-up 
by the time of database closure, with 5% lost to follow-up, 6% dead and 16% transferred out on 
treatment.  
Treatment durability: 
Among the children still in active follow-up by the end of the 1st, 2nd and 3rd years of treatment, 
92.8%, 87.7% and 80.9% respectively were still taking their initial regimen (Figure 1). In the first year 
on therapy, drug substitution was mainly due to potential drug interaction (2.9%) (e.g. changing 
from LPV/r to either LPV/r boosted with ritonavir or ritonavir alone due to co-treatment with anti-TB 
drugs or vice versa when TB treatment was stopped). By the third year on therapy, the main reasons 
for drug substitutions other than treatment failure were toxicity (3.1%), potential drug interaction 
(2.6%), treatment simplification (2.3%) and other unspecified reasons (4.1%). Treatment 
simplification was due to: changes in treatment protocols especially during the early years of ARV 
roll-out (e.g. changing from AZT to d4T in first-line regimens when national guidelines 
recommending d4T-based first-line were introduced in 2004), child initiating on ART including LPV/r 
at < 3 years of age and changing to EFV after their third birthday to facilitate better adherence and 
preserve LPV/r for later use,  lack of refrigeration facilities required for certain syrups/solutions and 
receiving  more effective treatment where this was previously unavailable (e.g. children previously 













Reasons for substitution of different drug classes: 
Protease inhibitors: 
When competing risks analysis for different causes of drug substitution was undertaken, the main 
reason for changing LPV/r in the first year of therapy was potential drug interaction with TB therapy 
with a cumulative incidence of 2.8% by one year.  After the first year on ART, LPV/r was mainly 
changed due to treatment simplification (Figure 3). Like LPV/r, RTV was changed mainly due to 
potential drug interaction and treatment simplification (Figure 3).  
Nucleoside reverse transcriptase inhibitors:  
Apart from treatment failure, the main reasons for d4T changes were toxicity, simplification of 
treatment and potential drug interaction (cumulative probabilities: 1.4%, 0.5% and 0.1% respectively 
by the second year of ART) with the latter occurring only in the first 6 months o  therapy (Figure 4).  
Changes due to d4T toxicity were analysed in more detail as this drug has been found to be one of 
the main causes of toxicity among patients on ART [30] prompting the change in WHO treatment 
guidelines from d4T to abacavir (ABC) as first-line therapy. Toxicity was mainly due to 
hyperlactataemia (cumulative incidence: 0.45% after 2 years on ART), lipodystrophy (abnormal fat 
redistribution) (cumulative incidence: 0.41%) and peripheral neuropathy (Figure 5).  
AZT changes in the 1st 2 years were mainly due to toxicity and treatment simplification with 
treatment failure being more important after 1.5 years on ART (Figure 4). The cumulative probability 
of changing AZT due to toxicity was 2.8% by 2 years on ART (i.e. n=11/602 children who initiated 
therapy with AZT) (Figure 2) with the main reason being anemia. 
Non-nucleoside reverse transcriptase inhibitors: 
NVP was mainly changed due to potential drug interaction with TB therapy and toxicity (cumulative 
probabilities: 12% & 4.5% by 2 years on therapy) (Figure 3). NVP had the highest incidence of 
changes due to toxicity among children initiating therapy (i.e. n=10/259) mostly occurring early with 
the probability of a change being 2% by 6 months on ART. Toxicity was mainly due to 
hypersensitivity reactions and liver toxicity. Changes to EFV were due to toxicity and treatment 












cumulative probability of 0.7% by 2 years (i.e. n=17/3031 children who initiated therapy with EFV) 
(Figure 2) and were mainly due to hypersensitivity reactions, gastrointestinal and neuropsychiatric 
toxicities. 
Predictors of treatment-limiting toxicity: 
Multivariate models showed that the probability of d4T toxicity increased with age (adjusted hazard 
ratio (aHR): 3.80 for ≥ 3 years compared to < 3 years; 95% CI=1.04-13.85), baseline viral load (aHR: 
2.25 for each log increase compared to <400 copies/ml; 95% CI=1.11-4.57) and baseline WAZ (aHR: 
3.64 for each unit decrease in z-score; 95% CI=1.27-10.39). Additional adjustment for baseline liver 
function and WHO stage did not change the results. There was a reduced risk of treatment-limiting 
AZT toxicity among children who were not anaemic at ART start (aHR=0.09; 95%CI=0.02-0.55) and 
those in WHO stage 3 or 4 (aHR=0.14 compared to stage 1 or 2; 95% CI=0.03-0.77), after adjusting 
for baseline age. There were no predictors of NVP toxicity. 
DISCUSSION: 
Durability of initial ART in the first 3 years of treatment: 
ART durability among children on treatment in South Africa is good with about 80% of children who 
were in active follow-up continuing with their initial regimen after 3 years of therapy. This is slightly 
higher than that of adults; in South Africa 72% of adults remained on their initial regimen after 3 
years [4] and 51% of the Swiss HIV adult cohort after 1 year of ART [31]. This may in part be due to 
the lack of alternative first-line drugs, especially when compared with adult studies. By 2 years on 
ART; NVP, AZT and d4T were responsible for the most treatment-limiting toxicity (n=10/259 (4%), 
n=11/602 (2.8%) and n=45/4883 (1.4%) respectively). Our findings are similar to those from some 
paediatric cohorts in developing countries which report ART durability between 80%-99% [7, 8, 24] 
although having fewer children and shorter durations of follow-up than our study.  
Reasons for drug changes: 
Overall, reasons for drug substitution changed with duration of therapy. In the first year, the main 
reason was potential drug interaction while in the second year treatment failure, drug interaction 












Toxicity was a small, but important cause of treatment changes early on, but became more 
important by the 3rd year on treatment. NVP, AZT and d4T were the main causes of changes due to 
toxicity, while EFV, 3TC and the PIs were relatively well tolerated. This agrees with findings from 
adult studies that showed a higher risk of NVP changes due to toxicity compared to EFV [4, 34]. NVP 
toxicity occurred almost entirely in the first six months whereas d4T toxicity occurred mostly after 1 
year of therapy e.g. lipodystrophy only started occurring after 1 year. Half of the AZT toxicity 
occurred in the first 3 months with the remainder evenly spread over the following 21 months. 
The largest cause of toxicity late in therapy was lipodystrophy due to d4T as was the case in other 
studies conducted in similar settings [25, 35]. The timing of toxicity is similar to findings in a Ugandan 
study by Tukei et al (2012) except that more children (i.e. one third) developed toxicities in that 
study. A number of reasons may account for this difference:  our study only focuses on treatment-
limiting toxicity, not all toxicity which might result in finding lower incidences especially in the 
context of limited alternative drugs. In addition, in the Ugandan study physicians actively assessed 
children for toxicity especially in the first 3 months of treatment, whereas our study is based on 
routine programmatic data. In the busy clinics where our data is collected, laboratory tests to detect 
toxicity may not have been done as frequently or completely as in a dedicated toxicity study.  
Risk factors for stavudine, zidovudine and nevirapine toxicity: 
Age ≥ 3 years, higher baseline viral load and higher baseline WAZ were predictive of treatment-
limiting d4T toxicity. It is plausible that 2 of the major forms of d4T toxicity, namely lipodystrophy 
and peripheral neuropathy, are difficult to detect or do not occur in very young children. The finding 
of higher baseline WAZ being predictive of d4T toxicity concurs with adult studies in which higher 
baseline weight was associated with treatment-limiting d4T toxicity.  It is possible that fatter children 
were more predisposed to uneven distribution of fat after initiating ART with d4T-based regimens. 
for a Adult studies also suggest that female sex, advanced WHO stage [4, 6] and weight gain ≥5kgs in 
the first 3 months of therapy [4] are predictive of d4T changes due to toxicity.  Lack of anemia and 
advanced WHO stage were protective against treatment-limiting AZT toxicity. It is possible that 












limited to iron and folate hence preventing them from becoming anemic while taking AZT containing 
ART regimens. Like our study, adult studies found no predictors of treatment-limiting NVP toxicity. In 
contrast, Tukei et al (2012) found no significant baseline predictors of any ARV toxicity despite the 
children in their cohort being of similar age to ours.  
Unique challenges of paediatric ART: 
We found some unique reasons for treatment change that are not reported in adult studies, but 
have been reported from paediatric studies in settings similar to ours, and which increase the 
challenge of scaling up ART for children. Unlike adults, children’s ART drugs may be changed to 
simplify their treatment e.g. when a child grows older and can take tablets instead of syrups or when 
a child grows to >3 years or 10kg and can take EFV instead of other drugs [8, 12, 20]. In certain 
situations it may be safe to substitute PIs with NNRTIs after initial viral suppression, thus saving PIs 
for second-line treatment [33]. In clinical practice in South Africa, LPV/r is sometimes changed to EFV 
when children reach 3 years of age especially in children with difficulty adhering to LPV/r.  In this 
study, 7.3% of all changes made to LPV/r were a result of children growing older than 3 years and 
thus having their drug changed to EFV. 
In addition, liquid formulations may require refrigeration which is frequently unavailable in resource-
limited settings. This may necessitate off-label use of adult capsule formulations or syrups not 
requiring refrigeration for infants and young children (e.g. AZT) even if these are not part of 
nationally recommended first-line, with drug changes to simplify treatment once children are old 
enough to be dosed in fractions of tablets. Drug storage requirements together with more frequent 
drug changes make supply chain management of paediatric ARVs more complex and expensive. For 
example, while ritonavir boosted LPV/r appears to be the best treatment approach for children on 
LPV/r based regimens co-treated for TB, ensuring sufficient quantities of RTV is difficult since it has a 
short shelf-life [32]. Further, it is not used in any standard regimen, making supply-chain 












The burden on the procurement system of any paediatric ART program may be substantial and, as 
recommended first-line regimens change, it is important to monitor child-specific reasons for ART 
change to inform treatment and monitoring guidelines and drug procurement plans [37]. 
Parents and guardians also may have to frequently learn about different storage requirements for 
the new drugs, the different dosing of each drug and different administration methods, which may 
adversely affect adherence.   
Strengths and limitations: 
This is the largest longitudinal dataset of paediatric data evaluating ART durability, tolerability and 
safety from a programmatic setting in the developing world using WHO recommended drugs over a 
duration of 3 years, giving enough time and sufficient numbers for relatively long term complications 
and rarer toxicities to develop e.g. lipodystrophy from d4T only started occurring after 1 year in this 
cohort and could have been missed if follow-up duration was shorter. Some studies which 
investigated ART durability over shorter durations were unable to demonstrate metabolic 
complications of some drugs [36]. In this analysis, diet was not adjusted for and this may have 
confounded the assessment of drug-related dyslipidaemias. 
A substantial number of children were on PI-based first-line therapy which is unusual in resource-
limited settings. Competing risks analysis was used to assess the incidence of each reason for 
changes of a particular drug which prevented over-estimation of drug changes. This analysis was 
limited to children whose data in the IeDEA database was complete. It is possible that children with 
incomplete data or who were not captured may have had different outcomes. 
These data were routinely collected in busy HIV clinics where there may be inconsistencies in 
recording of data and different thresholds for drug changes due to toxicity between clinicians in the 
same site or across sites. Some reasons for drug substitution remained unascertained therefore 
there may be underestimation of various drug change reasons. In addition, there might be some 
differences in monitoring patients on ART and this may impact on frequency of and reasons for 
treatment changes, however, the clinics included in this analysis had similar frequencies of clinical 












might have varying alternative drug options leading to differences in their treatment change 
protocols. Furthermore, the absence of paediatricians specifically providing HIV care at most of the 
clinics might have contributed to the heterogeneity in changing regimens or individual drugs across 
cohorts. Differential loss to follow-up of children with versus without toxicity may have biased our 
results.  
A fairly large proportion of children were transferred out and censored at their last visit. This might 
have affected estimates of ART durability if treatment changes in these children differed from those 
retained in the cohorts. However, there is no reason to suspect that this was the case as standard 
South African national paediatric ART guidelines are generally followed at all down-referral sites. 
Using competing risks analysis limits the generalizability of the reasons for individual drug 
substitution to populations without similar competing risks/reasons for drug substitution. We 
specifically excluded examining treatment stops due to non-adherence in this study as it was difficult 
to distinguish in this routine monitoring data the difference between passive treatment 
interruptions due to missed visits and active stopping of treatment by the treating clinician due to 
non-adherence. A detailed study assessing the impact of poor adherence on treatment durability 
would be valuable. Similarly, as this study only looked at the first treatment change, it would be 
useful to examine subsequent treatment changes particularly after routine changes due to potential 
drug interactions and treatment simplifications.   
Conclusion: 
These findings suggest that paediatric ART durability in resource-limited settings is good but 
complex, with treatment changes not only due to toxicity, treatment failure and drug interactions, 
but also treatment simplification. Clinicians treating children need to be aware of the drugs 
commonly causing toxicity, notably NVP, AZT and d4T in order to specifically monitor for them and 
ensure timely substitution of the drugs. 
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Table 1: Patient characteristics of children at ART initiation in routine HIV care programs in South 
Africa (N=5517) 
  Number of children*  Median (IQR) 
Age (months) 5517 42(15-82) 
CD4 count (cells/mm3) 4498 388(174-723) 
CD4 Percent 4270 12(7.1-17.4) 
Weight-for-age z score 3838 -1.94(-3.24 to -0.97) 
log10 viral load 3757 5.3(4.7-5.9) 
  Number of children* Percent  
Gender (Males) 2825/5517 51%  
WHO stage 3 or 4 2911/3857 75% 
Severe immune suppression  3705/4594 80% 
Severe anemia at ART start 263/1365 19% 
"First" drug in regimen ** 
AZT 602/5517 10.9% 
d4T 4883/5517 88.5% 
ABC 32/5517 0.6% 
"Third" drug in regimen ** 
EFV 3035/5517 55% 
NVP 259/5517 4.7% 
RTV / LPV/r 2223/5517 40.3% 
*Not all variables were measured on all children 


















Table 2: Predictors of D4T changes due to toxicity over 3 years using Cox-proportional hazards 
regression among South African children on ART in routine HIV Programs (only children with at least 
one follow-up visit were included) 
Variable D4T (n=4623) 








4.40  0.001 1.78-10.87 3.64  0.016 1.27-10.39 
Baseline log10 viral 
load 
(median=5.61) 
1.69  0.093 0.92-3.12 2.25  0.025 1.11-4.57 
Age < 36 months 
(N=1987) 
1 
Age >=36 months 
(N=2636) 
2.62  0.24 1.14-6.06 3.80 (n=3165) 0.043 1.04-13.85 
a Hazard Ratio, b Confidence Interval 
Weight-for age-z score, viral load and age were measured at baseline. Age and sex-standardized 
weight-for-age z-scores (WAZ) were calculated using the WHO 2006 reference standards ; age was 
included as a binary variable with a cut-off at 36 months because of different regimens being 
prescribed for children <36 months and ≥36 months; increase in viral load copies was compared to 





















Table 3: Predictors of AZT changes due to toxicity over 3 years using Cox-proportional hazards 
regression among South African children on ART in routine HIV Programs (only children with at least 
one follow-up visit were included) 
Variable AZT (n=592) 
Unadjusted HRa p-value 95%CIb Adjusted HRa p-value 95%CIb 
WHO 3 or 4 (vs. 1 or 2) 
(N=441) 
0.35  0.150 0.08-1.46 0.14 0.024 0.03-0.77 
Severe Anemia   
(N=262) 
1 
 No severe anemia 
(N=76) 
0.12  0.013 0.02-0.64 0.09 0.009  0.02-0.55 
Age less than 36 months 
(N=408) 
1 
Age in months (≥36) 
(N=184) 
1.69  0.416 0.48-5.99 1.22 0.848  0.13-11.55 
a Hazard Ratio, b Confidence Interval 
WHO stage, degree of anemia and age were measured at baseline; severe anemia was defined as 
baseline haemoglobin (Hb) <7g/dl and age >21 days) and age was included as a binary variable with 
































Figure 1: Proportion of children who had drug stops/substitutions having remained in follow-up at 1, 
2 and 3 years of therapy in routine HIV care programs in South Africa. 
Among the children still in active follow-up by the end of the 1st, 2nd and 3rd years of treatment, 
92.8%, 87.7% and 80.9% respectively were still taking their initial regimen. The main reasons for 
treatment change other than treatment failure were drug interaction in the 1st and 2nd years of 
therapy while in the 3rd year of therapy; the main contributors were drug interaction, toxicity and 
treatment simplification. 
 
Figure 2: Drug substitution due to toxicity by drug over 2 years among South African children in 
routine HIV care programs (only children with at least one follow-up visit were included). 
Nevirapine had the highest probability of being changed due to toxicity followed by zidovudine and 
stavudine. Efavirenz caused the least toxicity. LPV/r and RTV are not on this graph due to almost no 
treatment-limiting toxicity (i.e. even less than EFV which is the lowest on the graph). 
 
Figure 3: LPV/r, RTV & NVP substitution over 2 years by reason among South African children in 
routine HIV care programs. 
The main reasons for changing lopinavir/ritonavir and ritonavir apart from treatment failure were 
potential drug interaction and treatment simplification while nevirapine was mainly changed due to 
toxicity and drug interaction with anti-tuberculosis drugs. 
 
Figure 4: d4T & AZT substitution over 2 years by reason among South African children in routine HIV 
care programs. 
Apart from treatment failure, the main reasons for stavudine changes were toxicity, simplification of 
treatment and potential drug interaction while zidovudine changes were mainly due to toxicity and 
treatment simplification. 
 
Figure 5: d4T substitution due to toxicity over 2 years by reason among South African children in 
routine HIV care programs. 
Treatment changes due to stavudine toxicity were mainly due to hyperlactataemia, lipodystrophy 



























Year of treatment 1 2 3 
Number followed 3226 1434 1065 
Substitution due to other reasons% 1.3 2.2 4.4 
Substitution due to treatment simplification% 1.2 1.9 2.3 
Substitution due to potential drug interaction% 2.9 2.6 2.6 
Substitution due to toxicity% 0.8 1.7 3.1 
Substitution due to treatment failure% 1.0 3.9 6.7 














Time on therapy, years 0 0.5 1.0 1.5 2.0 
NVP 256 192 156 121 95 
AZT 592 419 317 233 166 
d4T 4623 3489 2653 1948 1383 
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Stavudine changes due to toxicity
 
The liver toxicity, dyslipidaemias and peripheral neuropathy lines do not go up to 2 years because 
these toxicities occurred very early on during therapy and there were no further events beyond 1.5 
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 This document provides guidance on the preparation of data tables for the transfer of data 
for the IeDEA Southern Africa Collaboration. 
 It is requested that each clinic prepares ten separate tables with the new data, as described 
in detail below. While 6 of these tables should be submitted by all sites, tables 7 -10 will only 
be applicable to certain sites (see below).  
 The tables can be sent in the format that is most convenient for the site, including MS Excel, 
MS Access, ASCII etc. Please contact the IeDEA data manager if you have any queries.  
 It is appreciated that for some clinics it may be easier to send their data as they stand (for 
example in Excel) and to leave the data management and preparation of the ten tables to 
the data centre. This is not a problem, but it is requested that a separate document be 
included with a list of the variables in the dataset and brief descriptions/definitions.  
 It is accepted that there will be missing data for some patients, and even entire missing 
tables from some sites who simply do not have that data in electronic format.  
 It is requested that for security purposes, data tables be encrypted and compressed with 
WinZip 9 or higher using the AES encryption algorithm prior to sending.  The encryption 
password (minimum of 10 characters long, including upper/lower case, numbers and special 
characters) should be communicated to the relevant data centre contact person by fax or by 
telephone.   
 The use of UCT’s Vula site is encouraged; this is an open-source tool allowing for the secure 
transfers of data from sites to the Data Centre.  Vula is open and accessible 24 hours a day, 7 
days a week.   
 Please ensure that the dataset has been stripped of personal identifying information prior to 
sending. 
 Please include a unique anonymous identifier for each patient (PATIENT) for cross-reference 
with your own database. It can be the identifier you are using or a special identifier you 
create for IeDEA Southern Africa. This anonymisation key must be maintained by the site 
under secure conditions.  
 Sites treating children should please send the date at which they changed from using the 
WHO 3-stage clinical staging system to the 4-stage clinical staging system. 
 Thank you very much for your contribution to this collaborative project! 
Inclusion criteria for patients 












 Documented HIV-1 infection  
 Patients in care at the facility for whom the date of first visit at the facility is known exactly.  
Notes: 
 Where possible, it is intended that data be transferred on HIV-infected patients followed-up 
at the facility irrespective of whether or not they received highly active antiretroviral therapy 
(HAART). 
 When transferring data just on patients who received HAART, it is preferable to include 
patients irrespective of whether or not they were exposed to antiretrovirals before the 
recorded HAART start date. In other words treatment-naïve and treatment-experienced 
patients are included.  
 Sites should send all information on all patients (adults and/or children) in a single dataset. 
For adult patients (those whose first visit at your facility was after their 16th birthday) the 
paediatric specific fields (highlighted in blue) do not need to be completed (i.e. enter code 
88 – not applicable). Paediatric specific fields must be entered as completely as possible for 
all patients whose first visit at your facility is before their 16th birthday even if their follow-
up extends beyond the age of 16 years.  
 Some patients will have been in care at another facility prior to commencing care at your 
facility. These patients should be included in the d taset, noting against the relevant field 
that they have been transferred in. All treatment and opportunistic infection (OI) history 
prior to commencing care at the facility should be reconstructed as far as possible and 
entered in the appropriate tables, with unknown codes for dates of start and end date of 
OIs/antiretroviral drugs where necessary. 
Dates 
 The term baseline will not be used as this creates confusion. We will rather make use of a set 
of key dates that will be entered into the first table, the PATIENT table. These are: 
 
Variable name Definition of key date 
FRSVIS_DMY Date of first visit at your facility 
HIVP_DMY  
(HIVP_Y (year) and HIVP_M (month) if exact 
date unknown) 
Date of first positive HIV-1 test 













 For all fields that require a date, the precise date should be entered in the format  
dd-mm-yyyy if it is known. If the precise date is not known, the month and year should be 
entered separately as far as possible in the separate dedicated fields provided for these, and 
the precise date field should be left blank.  
 If month or both the year and month are unknown, the precise date field should be left 
blank and unknown codes should be entered into the year field (9999) and the month field 
(99) as appropriate.   
 For certain date fields a precise date is obligatory e.g. date of first visit at your facility 
(FRSVIS_DMY) and date of HAART initiation (HAART_DMY). In patients who commenced 
HAART at another facility, if the precise date of start of HAART cannot be estimated 
reasonably accurately, the patient should be entered as treatment experienced and the date 
of first visit at your facility will be regarded as the date of start of HAART. 
Definitions  
 HAART is defined as treatment with a combination of at least three drugs from any class or 
classes.  
 “Treatment experienced” is defined as previous exposure to any antiretroviral drug for at 
least 30 days, excluding exposure for prevention of mother to child transmission (PMTCT) or 
post-exposure prophylaxis (PEP). 
Standard codes 
Certain codes will appear repeatedly in a number of lists for coded fields. In this instance, the 





95 Not ascertained/Not collected at this facility 
99 Unknown despite attempting ascertainment  
88 Not applicable 
Data tables 
For each clinic, the following five to ten data tables or files should be prepared, depending on data 
availability.  
 Tables 1 to 5 are required by all sites.  












 Table 7 (PREGNANCY) is required only for sites that record information on pregnancy 
electronically.  
 Table 8 (PAR HEALTH) is required only for patients who commence care before their 16th 
birthday.  
 Table 9 (TB) is required only from sites that record detailed information on episodes of 
tuberculosis electronically.  
 Table 10 (TRIAL) is required only for sites where patients may be enrolled on clinical trials or 
research studies apart from cohort analyses of routinely collected data.  
 In addition, a table summarising with information on the overall cohort or “meta-data” for 
the transfer, should be included with all transfers. 
  
1. PAT (Patient data): A table containing socio-demographic data on patients, clinical 
characteristics at start of HAART in HAART-treated patients, as well as information on the 
outcomes of patients. One line will correspond to one patient. In other words, each patient 
will appear only once in this table. We propose that this table is called PAT.   
2. LAB (Laboratory data at baseline and follow-up): This is a single table containing all 
laboratory data: CD4, HIV viral load, and all other laboratory tests.  One line will correspond 
to one laboratory result. In other words, most patients will have multiple records in this 
table. We propose that this table is called LAB.  
3. ART (Antiretroviral treatments): A table with the data on all antiretroviral drugs that a 
patient has received or been exposed to including PMTCT (both exposure to mother as well 
as infant peri- or post-natal) or post-exposure prophylaxis. This includes treatment received 
at your facility and at other facilities.  The table will contain one line for each separate drug, 
with different fields for the drug name (code), the prescription start dates and stop dates.  
Most patients will have numerous records in this table.  The drug history of patients who 
commence care at your facility but have previously been treated at another facility should 
be reconstructed and entered into this table as far as possible. We propose that this table be 
called ART. 
4. OI (Opportunistic Events): A table with the information on all opportunistic infections or 
incident HIV-associated diagnoses. One line will correspond to one clinical event with 
different fields for the event type (code), the start dates and stop dates. It is anticipated that 
stop dates will often not be known. In other words, some patients will have more than one 
record in this table and some may have no records in this table. History of opportunistic 
events occurring prior to commencing care at your facility should be reconstructed as far as 












5. VIS (Visit data): A table containing information on all clinical visits (including the first visit at 
your facility). One line will correspond to one visit.  Most patients will have more than one 
record in this table. We propose that this table be called VIS. 
6. LINK (Linkage data): A table containing information on family members (partners, children 
and siblings) also receiving HIV care either within your cohort or at another site. All family 
members receiving HIV care should be included whether they are receiving care at an IeDEA 
collaborative site or at a non-IeDEA site. One line will correspond to one family member 
receiving HIV care. In other words, some patients will have more than one record in this 
table and some may have no records in this table. We propose that this table is called LINK.  
7. PREGNANCY (Pregnancy data): A table containing information on all pregnancies, including 
spontaneous abortions/miscarriages and terminated pregnancies, and their outcomes. One 
line will correspond to one pregnancy. Multiple pregnancies will each have a record in the 
table, with the outcome of the relevant foetus recorded. Some patients will have more than 
one record in this table, while others (including all males and children less than 10 years) will 
have no records in this table. We propose that this table be called PREGNANCY. 
8. PAR_HEALTH (Parental health): A table with information on parental health status. This 
table is only required for sites sending data on patients 15 years old and younger at their 
first visit to the facility.  This table is linked to the visit table, so ideally there is an update on 
parental health status at every visit. Alternatively, this table should be filled in at least once, 
either for the first visit at your facility or the date of start of HAART.  
9. TUBERCULOSIS (Tuberculosis data): A table with information on all episodes of tuberculosis 
(TB). This table is only for sites tha  record detailed information on TB episodes. Sites that do 
not collect detailed information on TB episodes should enter the TB episodes in the OI table. 
One line will correspond to one TB episode. In other words, some patients will have more 
than one record in this table and some may have no records in this table. We propose that 
this table be called TB. 
10. TRIAL (Enrolment in trials): A table with information on any trial or research study (apart 
from cohort analysis of routinely collected data) on which a patient is enrolled.  This table is 
only for sites running trials or research studies. One line will correspond to one 
trial/research study on which the patient is enrolled. In other words, some patients will have 
more than one record in this table and some may have no records in this table. We propose 
that this table be called TRIAL. 
11. OUTCOME_REVISED: (Death registry linkage data) A table with information on updated 
death status following linkage to registry systems. 












Variables to be included in core tables 
Socio-demographic characteristics and outcomes (PAT table) 
Table 1 below details the data that should be included in PAT table.  
The patient identification variable (PATIENT) must be unique, and it cannot be missing in any of 
the tables. This field must contain a unique and anonymous patient identifier; the field must NOT 
contain their name or any other identifying information. It is up to the local collaborator to 
maintain the key for linking the unique patient identifier with the patient. 
 
Table 1 – Variables to be included in PAT table 
Name Format and definitions Description 
PATIENT 
Text & numeric characters  
(based on cohort/site/patient 
identifier - FS) 
Unique, anonymous, patient identifier 
COHORT Text Text field identifying the cohort 
FACILITY Text 
Text field identifying particular clinic within 
cohort, if more than facility within the cohort 
BIRTH_DMY DATE (dd-mm-yyyy) 
Date of birth  
Enter exact date in this field if known. 
 If unknown leave blank and enter month and 
year as far as possible in fields below. 
BIRTH_Y 
Numeric (for example 1960) 
9995 = Not ascertained 
9999 = Unknown despite 
attempting ascertainment 
 
Year of birth 
BIRTH_M 
Numeric (for example 8) 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
Month of birth 
GENDER 
Numeric with codes: 
1 = Male 
2 = Female 
95 = Not ascertained 
99 = Unknown despite 













FRSVIS_DMY DATE (dd-mm-yyyy) 
Date of first visit at facility  
(Note: This date must be entered exactly) 
ENTRY 
Numeric with codes (see List 
1) 
Mode of entry to your facility 
ENTRY_OTHER Text Details of other mode of entry not listed in List 1 
MODE 
Numeric with codes (see List 
2) 
Most probable mode of  HIV transmission  
Name Format and definitions Description 
HIV_TYPE 
Numeric (for example 1) 
1 = HIV-1 
2 = HIV-2 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
Field to distinguish HIV-1 from HIV-2 
HIVP_DMY DATE (dd-mm-yyyy) 
Date of first positive HIV test 
Enter exact date in this field if known. 
 If unknown leave blank and enter month and 
year as far as possible in fields below. 
HIVP_Y 
Numeric (for example 2001) 
9995 = Not ascertained 
9999 = Unknown despite 
attempting ascertainment 
Year of first positive HIV-1 test 
HIVP_M 
Numeric (for example 8) 
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment 
Month of first positive HIV-1 test 
HIV_TEST 
Numeric with codes (IeDEA SA 
codes) 
1 = Presumptive diagnosis 
2 = Serology 
3 = PCR 
4 = P24 
5 = Rapid test 
90 = Other 












95 = Not ascertained 





0 =  Never started HAART 
1 =  Started HAART  
Conditional: 
If 1 then go to HAART_DMY 
HAART_DMY DATE (dd-mm-yyyy 
Date of HAART initiation 
(minimum 3 drugs together) 
Note: This date must be entered exactly. If 
patient commenced HAART at another facility 
and the exact date is not known, the patient 
should be entered as “Treatment experienced” 
in the EXP_Y field below and the first visit at your 
facility will be used as the start of HAART date. 
 
Name Format and definitions Description 
FHV_STAGE_WHO 
Numeric with codes: 
1 = Stage I 
2 = Stage II 
3 = Stage III 
4 = Stage IV 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
 
Clinical WHO stage (I to IV) at time of starting 
HAART 
 














Text (for example PCP - see 
List 3) 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
Stage defining illness-1 at time of starting 
HAART. 
(Enter 88 patients who have not commenced 
HAART) 
Note: At least FHV_S_SDI_1 should be 
completed in patients commencing HAART; A 
maximum of 4 stage defining illness can be 
entered in the 4 fields provided. There is no 
specific ordering to the entering of stage 
defining illnesses.  
FHV_SDI_2 
Text (for example PCP - see 
List 3) 
0 = No further stage defining 
illness 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
 
Stage defining illness-2 at time of starting 
HAART. 




Text (for example PCP - see 
List 3)  
0 = No further stage defining 
illness 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
 
Stage defining illness-3 at time of starting 
HAART. 




Text (for example PCP - see 
List 3)  
0 = No further stage defining 
illness 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
Stage defining illness-4 at time of starting 
HAART. 

















Name Format and definitions Description 
EXP_Y 
Numeric with codes: 
0 = No (No previous ARV 
experience ) 
1 = Yes (Treatment 
experienced, drug history 
known and recorded in ART 
table) 
2 = Yes (Treatment 
experienced, drug history not 
known)  
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
 
Patient is treatment experienced prior to starting 
HAART (HAART_DMY) ?   
Experienced = Any ARV drug for at least 30 days 
before starting HAART (PMTCT regimen and PEP 
excluded)  
This should be entered for all patients even 
those who have not commenced HAART.  
MTCT_Y 
Numeric with codes: 
0 = No (No MTCT exposure ) 
1 = Yes (MTCT exposed, drug 
history reconstructed  and 
recorded in ART table) 
2 = Yes (MTCT exposed, drug 
history not reconstructable)   
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
Patient exposed to MTCT drugs (either mother 
during pregnancy or infant peri- or post-natally) 
prior to start of HAART (HAART_DMY)? 
This should be entered for all patients even 













Numeric with codes: 
0 = No (No PEP exposure) 
1 = Yes (PEP exposed, drug 
history reconstructed  and 
recorded in ART table) 
2 =Yes (PEP exposed, drug 
history not reconstructable)   
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
Patient exposed to post-exposure prophylaxis 
(PEP) drugs prior to start of HAART 
(HAART_DMY)? 
This should be entered for all patients even 
those who have not commenced HAART. 
TB_FHV 
Numeric with codes 
0 = No 
1 = Yes 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
Patient was on treatment for TB at start of 
HAART (HAART_DMY) 
(Enter 88 patients who have not commenced 
HAART) 
WKS_TB_FHV 
Numeric (for example 8) 
88=Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment  
 
Duration in weeks since start of TB treatment 
when HAART was commenced in  patients with 
TB at start of HAART  
(Enter 88 for patients who have not commenced 
HAART or who did not have TB at start of HAART) 
Name Format and definitions Description 
PREG_FHV 
Numeric with codes  
0 = No 
1 = Yes 
88 = Not applicable 
95 = Not ascertained 




Pregnant at start of HAART 
(Enter 88 for men and children <10 years old 
AND all patients who have not commenced 
HAART) 
LAST_CONTACT_DMY DATE (dd-mm-yyyy) 
Date of last contact 













Numeric with codes (See List 
4) 
Type of last contact 
OUTCOME 
Numeric with codes (See List 
5) 
Outcome including death and loss to follow-up 
OUTCOME_DMY DATE (dd-mm-yyyy) 
Date of outcome  
(Leave blank if outcome is Alive [in care] or  
Alive [not in care])  
OUTCOME_Y 
Numeric (e.g. 2004) 
8888 = Not applicable or exact 
date of outcome entered 
above 
9995 = Not ascertained  
9999 = Unknown despite 
attempting ascertainment 
 
Year of outcome 
Enter 8888 for patients who have not died, or if 




88 = Not applicable or exact 
date of outcome entered 
above 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
 
Month of outcome 
Enter 88 for patients who have not died, or if 
exact date of outcome entered above. 
 
DEATH_C1 
Numeric with codes (see List 
6)   
Cause of death : 
Enter 88 for patients who have not died 
Note : There are 3 fields for 3 causes of death to 
be entered in no specific order. If an HIV-related 
cause of death is recorded, please ensure that 
the condition is recorded appropriately in the OI 
table.   
 
Nature of contribution of cause: 
For each cause of death, please characterise the 
contribution of the specific cause. 
 
DEATH_N1 
Text with following codes: 
I = Immediate cause 
U = Underlying 
cause/condition 
C = Contributing cause 
N = Not available 
DEATH_C2 
Numeric with codes (see List 
6) 
DEATH_N2 
Text with following codes: 












U = Underlying 
cause/condition 
C = Contributing cause 
N = Not available 
 
Name Format and definitions Description 
DEATH_C3 




Text with following codes: 
I = Immediate cause 
U = Underlying 
cause/condition 
C = Contributing cause 
N = Not available 
 
CAREG 
Numeric with codes (see List 
7) 
Primary caregiver at start of HAART 
(HAART_DMY) 
(paediatric patients only – enter 88 for adult 
patients) 
DISCL_CG 
Numeric with codes (see List 
8) 
Person informed of the HIV status of the child 
(paediatric patients only – enter 88 for adult 
patients) 
DISCL_CHILD 
Numeric with codes 
0 = No 
1 = Yes 
2 = In process 
88 = Not applicable (adult 
patient) 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
 
Was the child informed of his/her status at 
HAART_DMY? 
(paediatric patients only - enter 88 for adult 
patients) 
DELIV_M 
Numeric with codes 
10 = Vaginal, spontaneous 
11 = Vaginal, forceps 
Mode of delivery  













12 = Vaginal, vacuum 
20 = Caesarean section – 
primary/elective (before onset 
of labour and rupture of 
membranes) 
21 = Caesarean section – 
emergency 
22 = Caesarean section – type 
unknown 
88 = Not applicable 
95 = Not ascertained 




Numeric (e.g. 3.20) 
88 = Not applicable 
95 = Not ascertained 




Weight at birth in kg  
(paediatric patients only - enter 88 for adult 
patients) 
Name Format and definitions Description 
BRSTFD 
Numeric with codes 
10 = breastfeeding, exclusive 
11 = breast-feeding, 
exclusivity unknown  
12 = mixed feeding 
20 = Formula feeding 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown, despite 
attempting ascertainment 
Main infant feeding option after birth 
(paediatric patients only - enter 88 for adult 
patients) 
BRSTFD_ED DATE (dd-mm-yy)  
Date of cessation of breast feeding if applicable 
Leave blank if not applicable, child still being 












breastfed at all. 
BRSTFD_EST_DUR 
Numeric (e.g. 2) 
77 = still breast-feeding, ED 
unknown 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite 
attempting ascertainment 
Estimated duration of breastfeeding in months in 
children who are exclusively breastfed or mixed 
fed. 
(paediatric patients only - enter 88 for adult 
patients) 
Enter 88 if child still being breastfed or child not 
breastfed at all. 
 
Laboratory data (LAB table) 
Table 2 details the laboratory data that should be included in the LAB table.  All available data from 
the date of first visit should be included.   
Notes: 
 Results of laboratory tests must be provided in the units specified 
 Results of laboratory tests can be entered in one of two fields – a numeric field (LAB_V) and 
a coded text field (LAB_T) (for very high and/or undetectable viral loads, and for TB 
microscopy and culture results). 
 TB microscopy and culture results should only be entered in the coded result field (LAB_T) as 
follows, and not in the numeric field (LAB_V): 
 For viral loads, there is an additional field to indicate the lower limit of detection of the assay 
used. This field should be entered as not-applicable (Code = -88) for other laboratory results.  
 For TB sensitivity results, there are 2 additional fields. The first (TB_DRUG) where the drug to 
which sensitivity testing has been done is entered, and the second (SENS), where the 
sensitivity is recorded using the standard yes/no format. These fields should be entered as 
not-applicable (Code = 88) for other laboratory results.  
 Both CD4 percentage and absolute count should be included on paediatric patients until 
they are 16 years old. 
 There is no code for unknown values of for laboratory test results as tests of which the result 
is unknown should not be included in the dataset.  
 Only dates in the DMY format are permissible in this table. 
Table 2 – Variables to be included in the table LAB 
Name Format Description 
PATIENT Free (numerical or alphanumerical) Unique patient identifier 












Date when specimen was taken 
LAB_ID Text (see List 9) 
Code representing the measurement 
 
LAB_V Numeric (for example 44) 
Numeric value of measurement 
Leave blank if result entered as code (LAB_C) 
 
Name Format Description 
LAB_T 
Text  
Lower than limit of detection for viral 
loads should be entered as “LDL” 
TB microscopy and culture results 








 e.g. “> 6 000 000” or “P+++” 
Leave blank if result entered as number (LAB_V) 
RNA_L 
Numeric 
-88 = Not applicable 
-99 = Unknown 
Lower limit of detection of RNA assay 
(Enter -88 for laboratory tests other than viral 
load) 
TB_DRUG 
Text with codes: 
INH_L = Isoniazid low dose 
INH_H = Isoniazid high dose 
INH_U = Isoniazid – dose unspecified 
PZA = Pyrazinamide 
RIF = Rifampicin 
ETN = Ethionamide 
ETB = Ethambutol 
STREP = Streptomycin 
QUI = Quinolone 
88 = Not applicable 
TB Drug against which sensitivity has been 
tested.  
(Enter 88 for laboratory tests other than viral 
load) 
DRUG_RES 
Numeric with codes: 
0 = No (Sensitive) 
1 = Yes (Resistant) 
Is Mycobacterium TB cultured RESISTANT to 
drug in TB-DRUG field? 












88 = Not applicable load)  
 
Antiretroviral drug variables (ART table) 
Table 3 details the data on antiretroviral treatment that should be included in the ART table. As 
previously mentioned, preferably we will receive one line per drug, each with its prescription, start 
and stop date.   
Notes: 
All antiretroviral drugs to which a patient has been exposed (including PMTCT exposure of both 
pregnant women and infants peri- or postnatally) and PEP should be included with either the dates 
of starting and stopping the individual drugs, OR the number of doses OR the duration of treatment.  
 History of exposure to antiretroviral drugs prior to commencing care at the reporting facility 
should be reconstructed as far as possible and included in this table, making use of 
appropriate drug codes for unknown regimens and date/time codes for unknown start and 
stop dates or unknown durations.  
 
Table 3 – Variables to be included in ART table 
Name Format Description 
PATIENT 
Free (numerical or 
alphanumerical) 
Unique patient identifier 
ART_ID ATC (for example NVP – see List 
10) 
Type of antiretroviral drug 
ART_SD_DMY Date(dd-mm-yyyy) Date of starting each antiretroviral drug (start date). 
Enter exact date in this field if known. 
 If unknown leave blank and enter month and year as 
far as possible in fields below. 
Name Format Description 
ART_SD_Y Numeric (e.g. 2003) 
8888 = Exact start date entered in 
appropriate field 
9999 = Unknown despite 
attempting ascertainment 
9995 = Not ascertained 
Year of starting drug 












88 = Exact start date entered in 
appropriate field 
99 = Unknown despite attempting 
ascertainment 
95 = Not ascertained 
ART_RS Numeric with codes  
(See List 11) 
Reason for receiving ART  
ART_FORM Numeric with codes  
1 = Tablet/capsule 
2 = Syrup/Suspension 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Type of formulation 
ART_COMB Numeric with codes  
1 = Individual drug 
2 = Part of a fixed dose 
combination  
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Is drug part of a fixed dose combination? 
ART_ED_DMY Date(dd-mm-yyyy) Date of stopping each antiretroviral drug (end date) 
Enter exact date in this field if known. 
 If unknown leave blank and enter EITHER month and 
year as far as possible in fields below OR number of 
doses OR duration in weeks in the appropriate fields.  
ART_ED_Y Numeric (e.g. 2004) 
8888 = exact end date or number 
of doses or duration in weeks 
entered in appropriate fields 
9999 = Unknown despite 
attempting ascertainment 
9995 = Not ascertained 
Year of stopping drug 
ART_ED_M Numeric (e.g. 7) 
88 = exact end date or number of 












doses or duration in weeks 
entered in appropriate fields 
99 = Unknown despite attempting 
ascertainment 
95 = Not ascertained 
 
Name Format Description 
NO_DOSES Numeric (e.g. 1) 
888 = end date or duration in 
weeks entered in appropriate 
fields 
999 = Unknown despite 
attempting ascertainment 
995 = Not ascertained 
Number of doses of drug e.g. 1 for single dose 
Nevirapine 
NO_WEEKS Numeric (e.g. 12) 
888 = end date or number of 
doses entered in appropriate 
fields 
999 = Unknown despite 
attempting ascertainment 
995 = Not ascertained 
Number of weeks of receiving drug  
e.g. 12 for AZT from 28 weeks of pregnancy delivering 
at term 
ART_END_RS Numeric with codes  
(See List 12) 
Reason for stopping antiretroviral drug 
INFO_SOURCE Numeric with codes  
1 = Clinical records at this facility 
2 = Clinical records/letter from 
      another facility 
3 = Patient/caregiver report 
4 = Likely protocol in use 
90 = Other 
99 = Unknown 













Opportunistic events (OI table) 
Table 4 below details the data on opportunistic events or HIV associated conditions diagnosed 
during follow-up that should be included in table OI. 
History of opportunistic events prior to commencing care at the reporting facility should be 
reconstructed as far as possible and included in this table, making use of appropriate date/time 
codes for unknown start and end dates. It is anticipated that the end date of OIs will frequently be 
unknown.  
Table 4 – Variables to be included in OI table 
Name Format Description 
PATIENT Free (numerical or alphanumerical) Unique patient identifier 
OI_ID 
Text (for example PCP - see List 3 – Disease 
codes – under PAT table)  
Type of opportunistic event 
OI_SD_DMY Date(dd-mm-yyyy) 
Date of start of each opportunistic event. 
Enter exact date in this field if known. 
 If unknown leave blank and enter month 
and year as far as possible in fields below. 
OI_SD_Y 
Numeric (e.g. 2001) 
 
8888 = Not applicable 
(Exact date entered in field above) 
9995 = Not ascertained 
9999 = Unknown despite attempting 
ascertainment 
Year of start of event 
OI_SD_M 
Numeric (e.g. 11) 
 
88 = Not applicable  
(Exact date entered in field above) 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Month of start of event 
OI_ED_DMY Date(dd-mm-yyyy) 
Date of end of each opportunistic event. 
Enter exact date in this field if known. 
 If unknown leave blank and enter month 












If OI is ongoing (has not yet ended) leave 
blank and enter appropriate code in field 
below 
Name Format Description 
OI_ED_Y 
Numeric (e.g. 2001) 
 
8885 = Ongoing 
8888 = Not applicable 
(Exact date entered in field above) 
9995 = Not ascertained 
9999 = Unknown despite attempting 
ascertainment 
Year of end of event 
OI_ED_M 
Numeric (e.g. 11) 
 
85 = Ongoing 
88 = Not applicable  
(Exact date entered in field above) 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Month of end of event 
DIAG_METH Numeric (see List 13 ) Method of diagnosis 
 
Follow-up clinic visits (VIS table) 
Table 5 below details the information to be included in the VIS table. Please include all visits for each 
patient since the first visit at the reporting facility, and where possible visits at previous facilities. 
Weight, height and head circumference left blank will be assumed to have not been ascertained. 
 
Table 5 – Variables to be included in VIS table  
Name Format and definitions Description 
PATIENT Free (numerical or alphanumerical) Unique patient identifier 
VISIT_DMY Date (for example dd/mm/yy) Date of visit patient 
VISIT_FAC 
Numeric with codes 
1 = Visit at this cohort’s facility 












2 = Visit at another facility 
99 = Site of visit unknown 
WEIGHT Numeric (for example 75) Weight in kilos (kg) 
HEIGHT Numeric (for example 75) Height in centimeters (cm) 
CTX 
Numeric with codes : 
1 = yes 
0 = No 
95 = Not ascertained 




Numeric with codes : 
1 = Yes 
0 = No 
95 = Not ascertained 




Numeric with codes : 
1 = Yes 
0 = No 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Fluconazole status 
HEADC Numeric (for example 75) Head circumference in centimeters (cm) 
SCHOOL_Y 
Numeric with codes 
 
0 = No school 
1 = At school 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Schooling for children >5 years.  
For adults and children less than 5 years,  
enter 88. 
LINK_REL Numeric with codes (See List 14) 
 












LINK_COHORT Text with codes (See List 15) 
Cohort within which family member is receiving 
HIV care 
LINK_ID 
Free (numerical or alphanumerical) 
-88 = Not applicable 
-95 = Not ascertained 
-99 = Unknown despite attempting 
ascertainment 
Unique patient identifier of family member 
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Abstract: 
(about 100 words) 
With the scale up of antiretroviral therapy (ART) for children in sub-
Saharan Africa, there are important concerns about its tolerability 
and durability.  There is a paucity of information about the 
frequency of and reasons for single drug or whole regimen changes 
for reasons other than treatment failure in children.  There are few 
available and palatable options of ART for HIV-infected children.  
There is therefore a need to understand the probability of and 
reasons for drug substitutions among children on ART to inform 
treatment and monitoring guidelines and prevent early and frequent 
substitutions, thus saving the few alternative and second-line drugs 
for situations of treatment failure.  We aim to use data from South 
African IeDEA collaborating sites which includes approximately 6000 
children initiated on ART, with 30% on protease inhibitor (PI)-based 
first-line therapy, to determine the drug-specific probability of and 













(about 1000 words) 
1. Background 
Southern Africa has a high burden of paediatric HIV, and, despite recent 
massively expanded access to antiretroviral therapy (ART), coverage 
remains low  [1].  The 2010 Joint United Nations Programme on 
HIV/AIDS (UNAIDS) South Africa Country progress report showed 
that there were 86, 270 children on ART by November 2009. 
Tolerability, safety and durability of first-line ART regimens are vital 
to scaling up ART and maintaining children on therapy.  Regimen 
durability is particularly important in resource-limited settings with 
limited drug options [2], especially in children [3]. 
Prospective cohort studies done in the developed world show that the 
main reasons for ART regimen change in children are toxicity and 
treatment failure [4-8].  For example, in a nine year cohort of 49 
perinatally infected children on highly active antiretroviral therapy 
(HAART) 50% of the children had their regimen changed by 24 
months on treatment [7].  The reas ns for treatment change were 
toxicity in more than half of the children and virological failure (22% 
of regimen changes), with reasons for the remainder of changes 
being unspecified [7].  In contrast, a five year cohort study of 40 
perinatally-infected children receiving early HAART showed that 
47.5% of these children were still receiving their first HAART 
regimen five years later and the main reasons for regimen change 
included virological failure (40%), simplification to a PI-sparing 
regimen (45%) and toxicity (5%) [8].  In many studies from 
developed country settings, however, children have had pre-HAART 
ART with either monotherapy and/or combined therapy [4-6] which 
is different from the cohort that will be used in this analysis in which 
all children will be HAART naive. 
While there are no dedicated studies of ART safety and durability in 
children from developing countries, paediatric ART cohort outcomes 
studies from Sub-Saharan Africa have reported on frequency and 
reasons for drug substitutions.  All of these studies report low 
numbers of treatment changes with the reasons for drug changes 
including antiretroviral (ARV) toxicity, treatment failure, initiation or 
completion of tuberculosis treatment and change due to increasing 












receiving ART at primary health care centres in Lusaka, Zambia; 
found that of the 2938 children who started ART, 17.6% had a 
single-drug substitution of their nucleoside reverse transcriptase 
inhibitor due to toxicity, intolerance or problems with dosing.  The 
median time to substitution was 132 days after ART initiation.  
Children on an AZT-based regimen were more likely to have a 
substitution compared to those on a d4T-based regimen (Hazard 
Ratio, 2.8; 95% CI 2.3-3.3).  NVP-based regimens were substituted at 
a rate of 7.9/100 patient years (median time to substitution, 103 
[IQR, 43 to 262] days) [11].  
Many of these cohorts are small with limited follow-up duration and the 
majority of children started on NNRTI-based treatment.  In addition, 
only the overall proportion of changes has been described, with 
descriptions of the time to regimen change and reasons for change 
being limited [14].  We therefore aim to use data from South African 
IeDEA collaborating sites which includes approximately 6000 
children initiated on ART, with 30% on PI-based first-line therapy, to 
determine the drug-specific probability of and reasons for 
substitution.  While this analysis will report on all treatment 
changes, the focus will be on drug substitutions defined as changes 
in single drugs or whole ART regimens for reasons other than 
treatment failure.  An analysis of failure and switching to second-line 
therapy in this cohort has already been published [15]. 
2. Objectives and hypotheses 
 To determine the cumulative probability of changing one or more 
drugs from an initial ARV regimen for reasons other than 
treatment failure for each first-line drug among children on ART 
in South Africa. 
 To describe the reasons for changing one or more drugs from an 
initial ARV regimen for each first-line drug among children on 
ART in South Africa. 
 To describe the alternative regimen options available for use 
among children on ART and the proportions of children taking 
these regimens in South Africa. 












particular drug substitutions.  
3. Study design 
   3.1 Eligibility criteria 
The analysis will only include children with complete data merged from 
collaborating South African paediatric IeDEA sites.  
3.3.1 Eligibility criteria for children 
 Children who commence ART at <16 years of age. 
 HIV-infected children who are ART-naïve (except for PMTCT) at 
the time of joining the cohort. 
 HIV-infected children who initiate ART with a documented 
regimen of at least 3 ARV drugs. 
   3.3.2 Eligibility criteria for paediatric cohorts 
Cohorts that initiated ART in at least 25 ART-naïve HIV–infected children. 
 3.2 Key variables and definitions 
3.2.1 Brief description of children at commencement of ART 
These will include: 
 Gender and age. 
 Measures of disease severity e.g. WHO stage, CD4 percent or 
count, viral load. 
 Social variables – primary caregiver. 
 First-line regimens actually used. 
 Previous PMTCT exposure. 
3.2.2 Characteristics of children at time of treatment change 
These will include: 
 Gender and age. 
 CD4 cell count and viral load at the time of treatment 
change. 
 First-line treatment regimen used. 
 3.3 Outcomes 
 Treatment change. 
 Reasons for treatment change. 
3.4 Statistical methods 
Analysis of pooled retrospective data from South African IeDEA 
paediatric ART sites using the agreed IeDEA Southern Africa data 












account for between cohort variation and the hierarchical structure 
of the data.   
Where there is missing or inconsistent information about ART regimen 
and/or reasons for substitution, additional information will be 
sought from the individual treatment sites.  
 Characteristics of children at baseline will be described.  
 Characteristics of children at time of ART regimen change will be 
described.  
 The Kaplan-Meier method will be used to estimate the time from 
initiation of ART to first treatment change both for all regimen 
changes not due to failure and for individual drug changes e.g. 
changing from d4T to an alternative NRTI.  
 Cox-proportional hazards models stratified by site will be used to 
determine the predictors of particular regimen changes e.g. d4T 
changes. Where there is more than one cause of a particular 
regimen change, competing risk regression will be used to 
estimate the cumulative probability of each cause.  
 
    3.5 Sample size considerations 
No calculation done. We will include all children with available data.  
   3.6 Ethical considerations 
The data to be used for this analysis are anonymised and will be obtained 
from individual IeDEA sites each of which has existing Institutional 
Review Board (IRB) approval for contribution of data to IeDEA 
collaborative analyses.  
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APPENDIX D: Summary of reviewed studies Table 1: Paediatric studies from resource limited settings    
Study Eley  B. et al, SAMJ 2004 [24] Fassinou P. et al, AIDS 2004 [1] Puthanakit T. et al, Clinical 
Infectious diseases 2005 [25] 
Jooste J. P. et al, SAMJ 2005 [26] 
Countries South Africa Cote d’Ivoire (ANRS1244/1278 
Children’s cohort (Abidjan, Coˆ te 
d’Ivoire) 
Thailand (Northern) South Africa (Northern Cape) 
Number of participants 80 78  107 100 
Ages of participants Mean 4.2 years Median (range) 6.5 (0.7-15.2) 
years 
Mean (SD) 7.7 (2.7) years Mean (range) 5.5 (0.25-13) years 
Gender 61% males 56% males 43% males Not reported 
Follow-up duration Total follow-up time: 23.9 child-
years  
Total follow-up time:160.58 child-
years 
Total follow-up time:143.9 child-
years 
Total follow-up time:6 months 
ARVs used d4T/ lamivudine (3TC)/ritonavir 
(RTV) if  child < 10 kg or < 3 
years old or Efavirenz (EFV) if 
child > 10 kg or > 3 years old 
2 NRTIs with either nelfinavir 
(NFV) (n=61) or EFV (n=17) 
d4T/3TC/EFV or Nevirapine (NVP)  d4T /3TC/ + NVP (n=14) or EFV 
(n=48) or lopinavir/ritonavir 
(LPV/r) (n=38) 
Treatment changes made RTV changed to EFV  Not reported 5 children changed from NVP-
based to EFV-based regimens 
1 changed to Abacavir (ABC), ddI, 
3TC, LPV/r, 3  NVP to EFV, 1 
LPV/r to EFV, 1 NVP to LPV/r 
Reasons for initial regimen 
substitution or switch 
1 child had gastrointestinal (GI) 
disturbances i.e. persistent 
nausea and vomiting, 1 had 
treatment simplified due to 
failure to tolerate the taste 
12 changed once; 5 changed 
twice. 2 TB treatment, 2 drug 
shortage, 5 prescription 
simplification, 1 poor response to 
ART, 7 adverse effects: 
pancreatitis, persistent diarrhoea, 
hepatotoxicity,  EFV 
hypersensitivity, AZT-induced 
anemia 
5 severe adverse reactions: 
hypersensitivity, drug fever, 
grade 2 elevated liver enzymes 
and grade 3 neutropenia 
1 patient resistant to treatment 
due to previous exposure to NVP 
monotherapy and dual therapy 
in private sector; other reasons 
not reported 
Median time to change 
after ART initiation 
Not reported Not reported Not reported Not reported  
Dedicated to ART regimen 
changes 













  Table 2: Paediatric studies from resource limited setting continued     
Study Hansudewechakul R. et al, 
Vulnerable Children & Youth Studies 
2006 [7] 
Rouet F. et al, AIDS 2006 [2] Nyandiko W. M. et al , JAIDS 
2006 [19] 
O’Brien D. P. et al, AIDS 2006   
MSF cohort [13] 
Countries Thailand  Cote D’Ivoire (ANRS1244/1278 
Children’s cohort (Abidjan, Coˆ 
te d’Ivoire) 
Kenya  Cambodia, Kenya, Malawi, 
Mozambique, Thailand, 
Uganda, Burkina Faso and 
Zimbabwe 
Number of participants 110 78 1353 enrolled, 279 received 
ART 
6151 
Ages of participants Median age (IQR) 9.3 (7.2-10.7) 
years 
Median age (range )6.5 ( 0.7–
15.2) years 
Median age (95% CI ) 6 ( 0.4 -
13.7) years 
Median (IQR) 7 (4.6-9.3) years 
Gender 42% males 56.4% males 51% males 52%  males 
Follow-up duration All followed up for 12 months  Median (IQR) 36 (30-42) months Median 34 months (95% CI: 4.8 
months to 13.7 years). 
Median (IQR)  6 (2-12) months 
ARVs used 10% EFV-based triple therapy, 90% 
NVP-based triple therapy ( 89% as 
fixed-dose combination) 
2NRTIs/EFV (17children) or NFV 
(61 children) 
d4T or AZT/3TC/NVP  d4T/3TC/NVP 
Treatment changes made 5 from NVP to EFV 9 from NFV-based to EFV-based 
& 1 from NFV-based to LPV/r-
based 
Alternative regimens- not 
reported 
Alternative first-line regimen- 
not reported 
Reasons for initial regimen 
substitution or switch 
One had severe hypersensitivity, 4 
TB treatment with rifampicin 
NFV toxicity (6 children); 
treatment failure (4 children). 
No details provided regarding 
the toxicity 
 3 changed due to clinical and 
immunological failure  
Side effects (4%-46% children) 
across the different cohorts; no 
details reported about side 
effects 
Median time to change 
after ART initiation 
Not reported Med (IQR) 33 (16.5-36) months  Not reported Median (IQR) 1.4 (0.5-3.2) 
months 
Dedicated to ART regimen 
changes 














   Table 3: Paediatric studies from resource limited settings continued 
Study Bolton-Moore et al, JAMA 2007 
[23] 
Ble C., Acta Paediatrica 2007 [31] Reddi A. et al, BMC-Paeds 2007 
[4] 
Wamalwa D. et al, JAIDS 2007 
[20] 
Countries Zambia Tanzania  South Africa Kenya 
Number of participants 4270 enrolled, 2938 started ART 103 151 67 
Ages of participants Median 2.2 (IQR, 0.77 -3.8) years Range: 0.1-4.2 years Median(range) 5.7(0.3-15.4) 
years 
Median(IQR) 4.4 (2.4-6.0) years 
Gender 47.9% males 59% males  49% males 51% males 
Follow-up duration Median (IQR) 12.6(4.6-23) 
months 
12 months (no loss to follow-up) Median (IQR) 8(3.5-13.5) months Med (IQR) 9(3-15) months 
ARVs used 50.6% d4T/3TC/NVP  
38.1% AZT/3TC/NVP 
4.2%  AZT/3TC/EFV 
7.1% d4T/3TC/EFV 
36% AZT/3TC/NFV  
32% AZT/3TC/NVP  
d4T/3TC  plus either NVP/EFV 
/LPV/r/ RTV 
AZT/3TC/NVP or EFV ; d4T/3TC/ 
NVP or EFV, 2 children on TB 
therapy were given d4T/3TC/ABC 
1 child who had failed NVP 
perinatal prophylaxis was given 
AZT/3TC/ NFV 
Treatment changes made 10.1% on d4T changed to AZT; 
27.8% on AZT changed to d4T; 
8.6% on NVP changed to EFV 
59.3% had a treatment change 
(no details reported) 
11.3% (17 patients) had regimen 
changes to AZT/ddI plus EFV or 
LPV/r 
10 children changed at least one 
drug-not specified 
Reasons for initial regimen 
substitution or switch 
Drug intolerance, toxicity, dosing 
issues 
Concomitant anti-TB treatment; 
Toxicity (4 neutropenia, 11.4%, 2 
anemia, 5.7%); low CD4 count in 
one (2.6%). 
2 due to drug toxicity (AZT-
induced anemia; d4T-induced 
lactic acidosis); 7 due to 
treatment failure; 6 due to start 
or stop of TB treatment; 2 from 
LPV/r to EFV due to increasing 
age (<3 years) 
7 adverse effects e.g. NVP 
associated rash, AZT-induced 
anemia, ABC hypersensitivity;  2 
treatment failure; 1 to prevent 
interaction with TB treatment 
Median time to change 
after ART initiation 
6.1 [IQR, 2.7 to 12.6] months for 
d4T to AZT; 3.7 [IQR, 1.4 to 9.0] 
months for AZT to d4T; 3.4[IQR, 
1.4 to 8.7] months for NVP to EFV 
5.5 months (IQR not reported) Not reported Not reported  
Dedicated to ART regimen 
changes 












                  
 
                 Table 4: Paediatric studies from resource limited settings continued 
Study Prendergast A. et al, AIDS 2008 [30] Kumarasamy N. et al, Tropical Paediatrics 
2008 [21] 
Sauvegeot D. et al, Paediatrics 2009 [29] 
Countries South Africa India Africa, Asia 
Number of participants 53 67 3936 
Ages of participants Median (range) 0.12 (0.02–1.09) years Mean (SD) 6.28 (4.18) years Median (IQR) 2.6 (1.7-3.7) years 
Gender 53.3% males 61% males 52.9% males in both regions 
Follow-up duration 49 children followed up for one year; 
4 died 
Minimum 18 months   Median 10.5 (3.7-20.6) months 
ARVs used 94% AZT/3TC/NVP/NFV 
3 infants were not given NVP due to 
abnormal liver function at baseline  
41.8% 3TC/ d4T/ NVP   




16.2 % d4T/3TC/NVP  
41.8% AZT/3TC NVP  
20.9% d4T/3TC/EFV 
Treatment changes made Changed to ddI, ABC, LPV/r  The alternative first-line regimens given not 
reported;  19.4% changed to 2ND line 
protease-inhibitor regimens 
3.8% changed ≥1 first-line regimens  
Reasons for initial regimen 
substitution or switch 
5 Starting TB treatment,  3 AZT 
toxicity, 4 Virological failure 
25.4% of all children due to toxicity e.g. 
anemia, rash, lipoatrophy, diarrhoea, nausea, 
pruritus, headache 
Toxicity: AZT toxicity more frequent than d4T 
toxicity in African children while in Asian 
children, NVP toxicities were more frequent 
Median time to change after 
ART initiation 
Not reported  Not reported Median (IQR) 1.4 (0.7–5.7) months 
Dedicated to ART regimen 
changes 















Table 5: Paediatric studies from resource rich settings 
Study  Doerholt K. et al, 
HIV Medicine 
2002 [14] 
Van Rossum A.M.C. et 
al, Clinical Infectious 
diseases 2002 [15] 
Resino S. et al, Clinical Infectious 
diseases 2006 [16] 
Bracher L. et al, Scandinavian 
Journal of Infectious Diseases 2007 
[17] 
Chiappini E. et al, BMC 
Infectious Diseases 2009 [18] 
Countries 
/continents 
England Netherlands  Spain  Denmark  Italy  
Number of 
participants 




6.3 (0.6-16) years 
Median (range) 5.4 
(0.25-16.4) years 
By CD4 count: Mean (SD) years: 
<5%: 7.4 (0.5); 5-15%: 7.7 (0.6); 
15-25%: 6.9 (0.8); >25%: 4.9 (0.7) 
Median (range) 6.7 (0.1-15.6) years Median (IQR) 2.21 (1.37-4-76) 
years 
Gender 50% males 56% males 44.2% males  47% males Not reported  
Follow-up 
duration  
Not reported Minimum of 54.2 
children-years 
Not reported (lasted until early 
teens) 
245 patient-years Median [IQR] 5.96 (4.21–7.62) 
years 
ARVs used 60% HAART i.e. 
2NRTIs & 1PI or 2 
NRTIs & 1NNRTI 
(17 naïve, 15 non-
naïve); AZT/3TC/NFV 
(n=27);  AZT/3TC/ 
indinavir (IDV) (n=3); 
NFV/d4T/ddI (n=2)  
d4T/3TC/NFV or RTV or EFV d4T/AZT+3TC+NVP/EFV or one of 
RTV/(LPV/r)/NFV/Saquinavir(SQV)/ 
IDV 
AZT or d4T/3TC or ddI / NVP or 




line regimens not 
reported. 
IDV to RTV for 8 
children 
49.6% had treatment changes to 
their initial regimen (no details 
reported) 
50%  had regimens modified (no 
details reported) 
52.5% had treatment changes 









6 virological failure, 1 
toxicity (interstitial 
nephritis), 1 reluctance 
to swallow drug  
Not reported 22% virological failure, 57% 
toxicity, 7% non-compliance, 17% 
other reasons 
1 liver toxicity, 3 structured 
therapy interruption, 9 
simplification to a PI sparing 
regimen, 8 virological failure 
Median time to 
change after 
ART initiation 
Mean (SD) 11.5 
(9.5)months 
Median (range) 12 
(0.5-18) months 
Not reported  50% by 2 years on therapy while 
only 25% remained on initial 
regimen after 6 years of therapy  


















 Table 6: Adult studies from the developing world 
Study  Wester C. W. et al, JAIDS 2005 [27] Boulle A. et al, Antiviral Therapy 2007 
[9] 
Hawkins C. et al, JAIDS 2007 [28] 
Countries  Botswana South Africa  Kenya 
Number of participants 153 2679 (2 primary care sites) 1286 
Ages of participants Median (IQR) 36 (30-42)years Median 32 (28-38) years Median (range) 36 (18-70)years 
Gender 41% males 29% males 40.9% males 
Follow-up duration  Median 54 weeks for clinical outcomes; 63 
weeks for laboratory data 
Median (IQR)11.1 (6.9-18.6) months Median (range) 11.6 months (0.03-
24months) 
ARVs used 64%ddI + d4T with EFV/NVP 44% d4T/ 3TC/ EFV 
31% d4T/ 3TC/ NVP 
98.9% initiated with an NNRTI-based 
regimen 
Treatment changes made Changed to unused NNRTIs and NFV 28% had treatment changes (no 
details reported) 
54.5% had treatment changes (no 
details reported) 
Reasons for initial regimen 
substitution or switch 
Virological failure, opportunistic infections, 
poor adherence, toxicity: 31 due to  
severe peripheral neuropathy, with all 
patients on ddI + d4Tcontaining ART; 6% due 
to hepatotoxicity, with 2 patients on NVP-
containing ART; 4% were for pancreatitis, 
with both patients on ddI-containing ART; 7 
due to NVP-induced hypersensitivity; 4% due 
to severe anemia;  
 
8% toxicity; d4T toxicity was mainly 
due to hyperlactataemia, 
lipodystrophy & peripheral 
neuropathy 
11% contraindication 
40.6% Toxicities, 28.1% TB treatment 
interaction 
Median time to change after ART 
initiation 
Not reported 3 years Median (range) 2.7 (0.17-20.8) 
months 













 Table 7: Adult studies from the developing world continued 
Study  Zhou J. et al, HIV Medicine 2007 [8] Castelnuovo B. et al, JAIDS 2011 [12] 
Countries  Asia, Pacific region Uganda  
Number of participants 404 559 
Ages of participants 50% aged 31-40 years Median (IQR) 38 (33-44) years 
Gender 74% males 30% males 
Follow-up duration  586.9 person-years Median(IQR)  33 (24-34) months 
ARVs used 3 or more drugs containing at least one NNRTI & one NRTI 
but no PI. About 50% received d4T/3TC/NVP 
74% d4T/3TC/NVP;   
34% AZT/3TC/EFV 
Treatment changes made Most changed to  AZT/3TC/NVP and  <3% to PI-based 
regimens 
26.5% had treatment changes (no details reported) 
Reasons for initial regimen substitution or 
switch 
Virological failure; patient’s decision; non-compliance; 
toxicity including lipodystrophy, hepatitis, rash, 
pancreatitis, peripheral neuropathy, lactic acidosis, 
insomnia; others like pregnancy, financial problems, 
doctor’s decision, hospitalisation  
Drug toxicity especially due to d4T; treatment failure; TB 
concomitant treatment, pregnancy  
Median time to change after ART 
initiation 
Median (range) 8.7 (0.07–50.6) months for patients on 
d4T/3TC/NVP who changed one drug.  Rate  of change was 
lower in patients on NNRTI-based triple or more 
combination therapy than on PI-based treatment or on  
treatment containing three or more NRTIs 
Median (IQR) time to substitution due to toxicity was 21.9 
(13.4–32.8) months 
 












APPENDIX E: Manuscript instructions to authors 
BMC Pediatrics 
Instructions for authors 
Preparing main manuscript text 
General guidelines of the journal's style and language are given below. 
Overview of manuscript sections for Research articles 
Manuscripts for Research articles submitted to BMC Pediatrics should be divided into the following sections (in this 
order): 
 Title page 
 Abstract 
 Keywords 
 Background  
 Methods  
 Results and discussion 
 Conclusions 
 List of abbreviations used (if any) 
 Competing interests 
 Authors' contributions 
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Whole conference proceedings 
Smith Y (Ed): Proceedings of the First National Conference on Porous Sieves: 27-30 June 1996; Baltimore. Stoneham: 
Butterworth-Heinemann; 1996. 
Complete book 
Margulis L: Origin of Eukaryotic Cells. New Haven: Yale University Press; 1970. 
Monograph or book in a series 
Hunninghake GW, Gadek JE: The alveolar macrophage. In Cultured Human Cells and Tissues. Edited by Harris TJR. New 
York: Academic Press; 1995:54-56. [Stoner G (Series Editor): Methods and Perspectives in Cell Biology, vol 1.] 
Book with institutional author 













Kohavi R: Wrappers for performance enhancement and oblivious decision graphs. PhD thesis. Stanford University, 
Computer Science Department; 1995. 
Link / URL 
The Mouse Tumor Biology Database [http://tumor.informatics.jax.org/mtbwi/index.do] 
Link / URL with author(s) 
Neylon C: Open Research Computation: an ordinary journal with extraordinary aims. 
[http://blogs.openaccesscentral.com/blogs/bmcblog/entry/open_research_computation_an_ordinary] 
Dataset with persistent identifier 
Zheng, L-Y; Guo, X-S; He, B; Sun, L-J; Peng, Y; Dong, S-S; Liu, T-F; Jiang, S; Ramachandran, S; Liu, C-M; Jing, H-C (2011): 
Genome data from sweet and grain sorghum (Sorghum bicolor). GigaScience. http://dx.doi.org/10.5524/100012. 
Preparing illustrations and figures 
Illustrations should be provided as separate files, not embedded in the text file. Each figure should include a single 
illustration and should fit on a single page in portrait format. If a figure consists of separate parts, it is important that a 
single composite illustration file be submitted which contains all parts of the figure. There is no charge for the use of 
color figures. 
Please read our figure preparation guidelines for detailed instructions on maximising the quality of your figures. 
Formats 
The following file formats can be accepted: 
 PDF (preferred format for diagrams) 
 DOCX/DOC (single page only) 


















The legends should be included in the main manuscript text file at the end of the document, rather than being a part 
of the figure file. For each figure, the following information should be provided: Figure number (in sequence, using 
Arabic numerals - i.e. Figure 1, 2, 3 etc); short title of figure (maximum 15 words); detailed legend, up to 300 words. 
Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder to reproduce 
figures or tables that have previously been published elsewhere. 
Preparing a personal cover page 
If you wish to do so, you may submit an image which, in the event of publication, will be used to create a cover page 
for the PDF version of your article. The cover page will also display the journal logo, article title and citation details. 
The image may either be a figure from your manuscript or another relevant image. You must have permission from 
the copyright to reproduce the image. Images that do not meet our requirements will not be used. 
Images must be 300dpi and 155mm square (1831 x 1831 pixels for a raster image). 
Allowable formats - EPS, PDF (for line drawings), PNG, TIFF (for photographs and screen dumps), JPEG, BMP, DOC, PPT, 
















Each table should be numbered and cited in sequence using Arabic numerals (i.e. Table 1, 2, 3 etc.). Tables should also 
have a title (above the table) that summarizes the whole table; it should be no longer than 15 words. Detailed legends 
may then follow, but they should be concise. Tables should always be cited in text in consecutive numerical order. 
Smaller tables considered to be integral to the manuscript can be pasted into the end of the document text file, in A4 
portrait or landscape format. These will be typeset and displayed in the final published form of the article. Such tables 
should be formatted using the 'Table object' in a word processing program to ensure that columns of data are kept 
aligned when the file is sent electronically for review; this will not always be the case if columns are generated by 
simply using tabs to separate text. Columns and rows of data should be made visibly distinct by ensuring that the 
borders of each cell display as black lines. Commas should not be used to indicate numerical values. Color and shading 
may not be used; parts of the table can be highlighted using symbols or bold text, the meaning of which should be 
explained in a table legend. Tables should not be embedded as figures or spreadsheet files. 
Larger datasets or tables too wide for a portrait page can be uploaded separately as additional files. Additional files 
will not be displayed in the final, laid-out PDF of the article, but a link will be provided to the files as supplied by the 
author. 
Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls) or comma separated values 
(.csv). As with all files, please use the standard file extensions. 
Preparing additional files 
Although BMC Pediatrics does not restrict the length and quantity of data included in an article, we encourage authors 
to provide datasets, tables, movies, or other information as additional files. 
Please note: All Additional files will be published along with the article. Do not include files such as patient consent 
forms, certificates of language editing, or revised versions of the main manuscript document with tracked changes. 












Results that would otherwise be indicated as "data not shown" can and should be included as additional files. Since 
many weblinks and URLs rapidly become broken, BMC Pediatrics requires that supporting data are included as 
additional files, or deposited in a recognized repository. Please do not link to data on a personal/departmental 
website. The maximum file size for additional files is 20 MB each, and files will be virus-scanned on submission. 
Additional files can be in any format, and will be downloadable from the final published article as supplied by the 
author. We encourage authors to use formats which facilitate reuse. e.g. We recommend CSV rather than PDF for 
tabular data. 
Certain supported files formats are recognized and can be displayed to the user in the browser. These include most 
movie formats (for users with the Quicktime plugin), mini-websites prepared according to our guidelines, chemical 
structure files (MOL, PDB), geographic data files (KML).  
If additional material is provided, please list the following information in a separate section of the manuscript text: 
 File name (e.g. Additional file 1) 
 File format including the correct file extension for example .pdf, .xls, .txt, .pptx (including name and a URL of 
an appropriate viewer if format is unusual) 
 Title of data 
 Description of data 
Additional files should be named "Additional file 1" and so on and should be referenced explicitly by file name within 
the body of the article, e.g. 'An additional movie file shows this in more detail [see Additional file 1]'. 
Additional file formats 
Ideally, file formats for additional files should not be platform-specific, and should be viewable using free or widely 
available tools. The following are examples of suitable formats. 
 Additional documentation  












 Animations  
o SWF (Shockwave Flash) 
 Movies  
o MP4 (MPEG 4) 
o MOV (Quicktime) 
 Tabular data  
o XLS, XLSX (Excel Spreadsheet) 
o CSV (Comma separated values) 
As with figure files, files should be given the standard file extensions. 
Mini-websites 
Small self-contained websites can be submitted as additional files, in such a way that they will be browsable from 
within the full text HTML version of the article. In order to do this, please follow these instructions: 
1. Create a folder containing a starting file called index.html (or index.htm) in the root. 
2. Put all files necessary for viewing the mini-website within the folder, or sub-folders. 
3. Ensure that all links are relative (ie "images/picture.jpg" rather than "/images/picture.jpg" or 
"http://yourdomain.net/images/picture.jpg" or "C:\Documents and Settings\username\My Documents\mini-
website\images\picture.jpg") and no link is longer than 255 characters. 
4. Access the index.html file and browse around the mini-website, to ensure that the most commonly used 
browsers (Internet Explorer and Firefox) are able to view all parts of the mini-website without problems, it is 
ideal to check this on a different machine. 
5. Compress the folder into a ZIP, check the file size is under 20 MB, ensure that index.html is in the root of the 














Style and language 
General 
Currently, BMC Pediatrics can only accept manuscripts written in English. Spelling should be US English or British 
English, but not a mixture. 
There is no explicit limit on the length of articles submitted, but authors are encouraged to be concise. There is also no 
restriction on the number of figures, tables or additional files that can be included with each article online. Figures and 
tables should be numbered in the order in which they are referred to in the text. Authors should include all relevant 
supporting data with each article. 
BMC Pediatrics will not edit submitted manuscripts for style or language; reviewers may advise rejection of a 
manuscript if it is compromised by grammatical errors. Authors are advised to write clearly and simply, and to have 
their article checked by colleagues before submission. In-house copyediting will be minimal. Non-native speakers of 
English may choose to make use of a copyediting service. 
Language editing 
For authors who wish to have the language in their manuscript edited by a native-English speaker with scientific 
expertise, BioMed Central recommends Edanz. BioMed Central has arranged a 10% discount to the fee charged to 
BioMed Central authors by Edanz. Use of an editing service is neither a requirement nor a guarantee of acceptance for 
publication. Please contact Edanz directly to make arrangements for editing, and for pricing and payment details. 
Help and advice on scientific writing 
The abstract is one of the most important parts of a manuscript. For guidance, please visit our page on Writing titles 












Tim Albert has produced for BioMed Central a list of tips for writing a scientific manuscript. American Scientist also 
provides a list of resources for science writing. For more detailed guidance on preparing a manuscript and writing in 
English, please visit the BioMed Central author academy. 
Abbreviations 
Abbreviations should be used as sparingly as possible. They should be defined when first used and a list of 
abbreviations can be provided following the main manuscript text. 
Typography 
 Please use double line spacing. 
 Type the text unjustified, without hyphenating words at line breaks. 
 Use hard returns only to end headings and paragraphs, not to rearrange lines. 
 Capitalize only the first word, and proper nouns, in the title. 
 All pages should be numbered. 
 Use the BMC Pediatrics reference format. 
 Footnotes are not allowed, but endnotes are permitted. 
 Please do not format the text in multiple columns. 
 Greek and other special characters may be included. If you are unable to reproduce a particular special 
character, please type out the name of the symbol in full. Please ensure that all special characters used are 
embedded in the text, otherwise they will be lost during conversion to PDF. 
Units 
SI units should be used throughout (liter and molar are permitted, however). 
 
 
